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- CHAPTER 1-
INTRODUCTION 
In the 19th century, age-related maculopathy (ARM) was described for the first time as an age-
related abnormality of the macula lutea. 1.2 ARM consists of a variety of clinical signs, from the early 
stages with soft distinct drusen, indistinct drusen and pigment alterations up to the late stages of 
geographic atrophy and neovascular macular degeneration. These late stages are also referred to as 
age-related macular degeneration. 3 Nowadays, ARM is the leading cause of blindness among the 
elderly in the Western world.' With the rapidly growing popUlation of the elderly, it can be 
estimated that in the Netherlands ahnost 115,000 people will have signs of the end stages in the year 
2030.' This will have great implications for the quality of life of these patients, since age-related 
macular degeneration decreases central vision. Furthermore, treatment is only limited to a small 
group of patients. 
Although many investigators have tried to unravel the pathogenesis of ARM, the knowledge of its 
etiology is still limited. Many environmental factors have been implicated as risk factors in ARM, 
however limited factors were consistent. 6,7 While already in 1875 the first description of a genetic 
component in ARM was given by Hutchington and Tay/ it was only since the last decade that 
research on the genetic factors in ARM has gained worldwide attention. Studies on the genetics of 
ARM have been hampered by the lack of suitable patient material and insight in complex diseases 
such as ARM. 
The aim of this thesis is to obtain more knowledge on the disease frequency and its risk factors. 
Special attention is addressed to the genetic factors involved in ARM. The first part of this thesis 
gives an overview of the current knowledge on the genetics of ARM. In the second part the disease 
frequency and its risk factors are described. The third part covers two genetic-epidemiological 
approaches to study the genetics of ARM. The fourth part addresses two candidate genes for ARM. 
The first, TIMP-3, was studied in a large pedigree with Sorsby fundus dystrophy, which is a disease 
with clinical signs similar to ARM. The second candidate gene, ABCR, was studied in patients with 
diseases which are related to ARM, as well as in a large combined population with ARM. Finally, a 
general discussion concerning the main findings and methodological issues is given in the last part, 
together with suggestions for future research. 
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GENETICS OF AGE-RELATED MACULOPATHY 
A REVIEW 
INTRODUCTION 
Age-related maculopathy (ARM) is the leading cause of pennanent visual impairment among the 
elderly in western countries. I-6 ARM is a degenerative disorder affecting the macula that is 
characterized clinically by soft drusen, hypo and hyperpigmentations of the retinal pigment 
epithelium (RPE) and retina in the early stage, and by geographic atrophy, choroidal 
neovascularisatiol1, pigment epithelium detachment and subsequent fibrous scarring of the macula 
in the late stage. These changes are all manifestations of the disease ARM, but the term age-related 
macular degeneration (AMD) is only used for the late stage. Age-related macular degeneration can 
be divided in two forms, geographic atrophy ("dry" fmID) and neovascular macular degeneration 
(also called IIwet!! [orm),7.9 This end stage is not always easily distinguishable from other macular 
disorders as any chorioretinal inflammation or scar may result in the growth of a subretinal 
neovascular membrane. Therefore, neovascular macular degeneration sometimes resembles myopic 
macular degeneration, pseudoxanthoma elasticum, Paget disease, Stargardt disease, Best disease, 
juxtafoveolar telangiectasia, adult foveomacular dystrophy, pattern dystrophy, presumed ocular 
histoplasmosis syndrome, ocular toxoplasmosis, central areolar choroidal sclerosis, laser 
photocoagulation scars as well as more rare traumatic, inflammatory, toxic, and congenital 
processes.S,IO,1I These disorders have to be excluded before the diagnosis of AMD can be made. 
Moreover, there are racial differences in clinical expression. In the Japanese drusen accompanying 
AMD are rarer than in Caucasians. 12 In the Inuit there is often progressive peripapillary geographic 
atrophy, including the macular area in the later stages of the disease. l3 
Due to leakage from choroidal neovascularisation blurring or distortion of central vision can 
OCCUI. The loss of vision is irreversible and is the result of degeneration of the photoreceptors in the 
macular area which occurs when the retinal pigment epithelium cells with which they are associated 
deteriorate and die. 
The prevalence of AMD increases with advancing age. It affects less than one percent of 50 
- 60 years oIds, and up to 10 percent of those over age 85. 14•24 Studies suggest that racial variation 
exists in the frequency of ARM. ARM is rare among blacks and Hispanic Americans."'" Incidence 
increases with aging and is estimated to be I per 1000 person years in 50-60 year olds, and 11.2 per 
1000 person years in individuals older than 85.30,31 
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The growing population of the elderly and increased life expectancy necessitates research into the 
causes and risk factors of this disease. In the Rotterdam Study, Klaver et al studied the importance 
of ARM in relation to visual decline as a function of age. In subjects older than 75 A1vID was the 
most important cause of incurable blindness. The impact grew with further increasing age to a 
prevalence of 6% of bilateral blindness or visual impainnent due to AMD in those aged 85 and 
over,5 This fact underscores the pressing need for research into potential causative factors of and 
treatments for AMD. 
Although certain risk factors have been identified, no interventions have been proven 
effective in preventing AMD. Laser photocoagulation and photodynamic therapy have been 
established as an effective treatment, but the use of the former is confined to a small proportion of 
patients with the exudative form of AMD, and the long-term benefits are limited or unknown. 32.43 
Besides age, smoking was found in all studies to be associated with AMD.44-58 Other risk factors for 
AMD have been identified, but not consistently, These risk factors are cardiovascular factors, such 
as elevated blood pressure, obesity, history of cardiovascular disease, as well as estrogens and light 
exposure.45 ,46,59.64 Also some ocular factors have been identified as possible risk factors for AMD, 
such as iris color, refractive error and cataract surgery.25,45,46,50,65.74 Besides these risk factors, genetic 
factors playa role in the etiology of AMD. 
The aim of this review is to give an overview of the various methods of locating the genes 
involved in AMD and to summarize the results of studies on genetics and AMD. 
METHODOLOGICAL ISSUES 
Since ARM develops only after the fifth decade of life, the study of heritability and genetics in 
ARM is difficult. The molecular genetic analyses have been hampered by the complexity of the 
diagnosis, multifactorial or polygenic inheritance, and the lack of muItigenerational data within 
families. 75.77 In most cases the parents of the patients are deceased, while in the younger generations 
the disease has not yet manifested itself on a clinical level. Most families available for genetic 
studies are therefore limited to sibpairs. Another problem is the uncertainty about unaffected people, 
because it is never known which subjects might develop ARM in the near future. All apparently 
unaffected individuals, should be considered as persons with an unknown affection state for the 
pmpose of genetic analysis. 
In general, the methods available for genetic dissection of complex traits such as AMD can 
be divided into four categories: linkage analysis in families, allele sharing methods in sibpairs, 
association studies in human populations, and genetic and biological analysis of large crosses in 
model organisms such as mouse and rat. 78·85 An overview of these methods is given in Table 1. 
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Table 1 Overview of analysis methods used for genetic diseases. 
Linkage analysis Allele sharing methods Association studies 
study population families related cases unrelated cases compared with 
unrelated controls from a general 
population 
scope of the method identifIcation of loci or genes applicable as linkage analysis or as contribution of mutations in 
causing the disease by positional association study candidate genes to the disease 
cloning 
a priori knowledge inheritance pattern non parametric non parametric 
type of genetic mechanism monogenic to oligogenic monogenic tal multifactorial multifactorial 
disadvantage - no direct conclusions for the - no direct conclusions for the - not appropriate for genomic 
general population general population screening 
- families with enough meiosis - many sibpairs and markers are - only applicable if candidate genes 
needed needed for genome screening are known 
advantage - very robust method for - sibpairs are easier to ascertain - data collection is relatively easy 
mendelian inheritance than families - direct conclusions for general 
- applicable in genetic isolates - applicable in genetic isolates population 
- applicable for genomic screening 
--
--- -- --
Chapter 2 Genetics of age-related macu/opathy; a review 
In linkage analysis a transmission model is constructed to explain the observed inheritance of a 
disease in pedigrees.86-89 The model is relatively straightforward for monogenic Mendelian 
inheritance but can become complicated for complex traits, because it may be difficult to construct 
a precise model that adequately explains the observed inheritance pattern. In linkage analysis the 
relationship of two or more markers or genes on a chromosome is investigated; the closer together 
genes or markers are, the lower the probability that they will be separated by recombination during 
meiosis. Consequently, it is more probable that they will be inherited together (see figure l). 
Linkage analysis can be used to find the gene responsable for a disease by observing markers which 
are cosegregating with the disease in a pedigree. If they cosegregate in a significant number of 
meioses, then the disease-causing gene is likely to be closely localised to these markers. The 
likelihood that the observed inheritance of marker alleles and the inheritance of the disease are 
actually linked, compared with the likelihood that these observed inheritance patterns occur by 
random chance, is referred to as the LOD score (logarithm of the odds ratio for linkage).87.88 
Linkage analysis should be perfonned within families, because the specific marker allele linked 
with the disease generally varies from family to family, in accordance with the allelic distribution of 
the marker in the popUlation. Such a linkage within a family is unlikely to be attributable to 
systematic bias, because most genetic markers segregate codominally without any consequences for 
the phenotype, and marker information is collected by laboratory analysis of biologic samples, 
independently of disease status. 
1.1 1.2 
1i:1 11:2 11:4 11:5 11:6 
111:1 111:2 111_3 111,4 111:5 111:6 111:7 111:8 
Figure 1 An example of linkage analysis in a pedigree 
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Males are represented by squares and females are represented by circles. The symbols of affected 
individuals are blackened. The bars beneath represent the haplotypes and the digits the 
corresponding alleles. Alleles are the natural variation a/the DNA sequence at a certain locus (e.g. 
a marker). All individuals inherit one allele from their father and one from their mother. Therefore, 
one marker reveals per individual two alleles. The order of well-localized markers is generally 
known. Alleles from a group of closely linked markers in a known order and derived from one 
parent are usually inherit as a unit and form a haplotype. 
Individuals 1: 1 and 1:2 are the faunders of this family, the male is affected with a blackened 
haplotype with alleles 1,2,3 and 4. This entire haplotype is cosegregating with the disease in his 
affected son (II: 1) and daughter (11:6), both having the blackened haplotype with the alleles 1,2,3 
and 4. His other son (II:3) is unaffected and has the other haplotype (with alleles 2,5,4 and 5) 
derived from his father. In the third generation, the two affected daughters (III:2 and 3) of the 
affected male (11:1) do have at least a part of the blackened haplotype. This is also the case in 
individuals III:6 and Il1:8. The fact that individuals II1:2 and 111:8 do have a part from both 
haplotypes from a single parent is caused by recombination. Recombination can occur during 
meiosis, in which part of the chromosomes (haplotypes) can be exchanged. The part of the 
chromosome which is cosegregating with the disease in this family is the blackened haplotype with 
allele 2 for the second marker and allele 3 for the third marker. In this family the disease-causing 
gene is probably located somewhere between the first and last marker. The recombination events 
define where the disease-causing gene is probably located. The more recombination events occur 
the more information can be obtained; however, part of the chromosome should be shared among 
the affected persons. 
If ARM is studied by linkage analysis in one large family, it may be assumed that one or two genes 
are involved, unless spouses introduce ARM into the pedigree. Unfortunally, for complex traits 
such as ARM, there are many variables that complicate linkage methods. These include the late age 
of onset, unknown gene frequency, reduced penetrance, possible mUltiple genes contributing to the 
development of the disorder (heterogeneity) and phenocopies (cases of ARM that arise from non-
genetic factors). For large family studies, the identification of mild cases might be essential to 
maximize the infonnativeness of the family and thereby increase the power. All unaffected 
individuals should be considered as unknown affection state. 
Allele sharing methods are based on the identical by descent (IBD) principle (see figure 2A 
and 2B) and involve testing whether affected relatives inherit a region IBD more often than 
expected under random Mendelian segregation.90 A special type of aIle sharing method is the 
affected sibpair analysis. The alleles of sibpairs, both affected with ARM, are compared with each 
other. If more than the expected 50% IBD allele sharing is revealed in a region, then the disease-
causing gene might be closely linked to this region . .In contrast with linkage analysis this method is 
non-parametric (that is, it assumes no model for the inheritance of the trait). 
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IBD is less sensitive for genetic complications or clinical misclassification than linkage analysis but 
is less powerful than a correctly specified linkage modeL 85,90 Sibling pairs for studies on ARM are 
in general easier to recruit than extensive pedigrees with affected family members, but for genomic 
screening many sibpairs are needed. 
Another special type of this method is allele sharing in a family originating from a 
genetically isolated population. In such a population the number of founders is limited, therefore the 
number of mutations or genes involved in ARM is decreased compared to the general population. 
The haplotypes of all affected individuals in such a large family are compared.'1 If a certain 
haplotype is cosegregating with ARM, then the disease-causing gene might be closely linked to this 
region. Confinnation of the diagnosis is critical in allele sharing methods, because the presence of 
confounding clinical subtypes can limit the power of the study to detect a major gene. It might be 
better to exclude ambiguous mild or subclinical cases of ARM at the cost of reducing the power of 
the analysis. 
1:1 1:2 
11:1 11:2 
:~D: 
Figure 2a Principle of identical by 
state (IBS) 
1:1 1:2 
11:1 11:2 
:~D: :~D: 
Figure 2b Principle of identical by 
descent (IBD) 
Figure 2A shows a small family consiting of two parents (individuals I: 1 and 1:2) with a son 
(individual 11;1) and a daughter (individual II;2). The son received alleles 1 and 4 from his father 
and alleles 2 and 6 from his mother. 
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The daughter also has allele 2, but she received this from her father (together with allele 5). These 
alleles 2 are identical by state, JBS (they both are allele 2, but received from a different parent). 
Figure 2B shows the same small family but the daughter has now received a different haplotype 
from her mother. Brother and sister both have alleles 2 and 6 received from their mother. These 
alleles are therefore not only identical by state but also identical by descent (JBD). 
Association studies are based on a comparison of unrelated affected and unaffected individuals from 
a population. Association studies test whether a particular allele or mutation is present at a higher 
frequency among affected as compared to unaffected individuals.84,85,87 In these genetic association 
studies, unrelated individuals are studied instead of families to test candidate genes. This facilitates 
data collection substantially. However, in genetical1y hetereogenous disorders multiple mutations in 
different genes may exist. This reduces the statistical power of genomic screens tremendously. 
Furthennore, for a genome screening one would need many markers close to one another in order to 
find a locus which would cosegregate among a part of the cases.92 For purposes of candidate gene 
screening association studies might be helpful. A problem with association studies in late-onset 
diseases is the selection of the control population. Unaffected individuals might develop the disease 
in the near future depending on their genotype which can lead to false negative results. Furthennore, 
genotypes of at least controls should be in Hardy-Weinberg equilibrium, which means that in the 
general population mating is random with respect to the gene in question. 87•93 
Experimental crossing and biological analyses of mice or rats offer an ideal setting for 
genetic dissection of mammalian pathology and physiology. With the opportunity to study hundreds 
of meioses from a single set of founders, the problem of heterogeneity is reduced, and more genetic 
interactions can be studied than is possible for human families. Unfortunately, no animal models are 
available for ARM. One of the problems might be that the experimental animals used for this kind 
of analysis usually do not become old enough to get ARM or do not have a macula. Such an animal 
would tremendously stimulate research into AMD. Also mice with knocked-out candidate genes 
would be very helpful. 
Recently, a knock out mouse of the ABCR gene was created.94 The ABCR gene is involved 
in Stargardt disease, cone-rod disease and in some types of retinitis pigmentosa, and it appears to be 
involved in some AMD cases.95-!02 Mice lacking the ABCR gene show delayed darkness adaptation, 
a transient accumulation of all-trans-retinaldehyde (all-trans-RAL) following light exposure, 
elevated phosphatidylethanolamine (PE) in outer segments, accumulation of a protonated complex 
of all-trans-RAL and PE (N-retinylidene-PE), and deposition of a major lipofuscin fluorophore 
(A2-E) in retinal pigment epithelium (RPE). These data suggest that ABCR functions as a flippase 
to eleminate N-retinylidene-PE from the disc interior, thus protecting the RPE from accumulation of 
lipofucsin. Delayed darkness adaptation is likeJy due to a transient accumulation in discs of the 
complex between opsin and all-trans-RAL. The authors concluded that ABCR-mediated retinal 
degeneration may result from tlpoisoningtl of the RPE due to A2-E accumulation, with secondary 
photoreceptor degeneration due to loss ofthe RPE support role." 
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One of the major advantages of experimental animal studies is that the pathogenesis of a disease can 
be more easily investigated and more genetic interactions can be studied. The major disadvantage is 
that animal models, if they do not exist in nature, are difficult to obtain. A gene or protein has to be 
known in order to be able to produce a knock-out animal or a transgenic animal. 
As ARM consists of a variety of clinical symptoms and is a complex disease, some of which 
have to be overcome in order to study the genetics of ARM. Linkage analysis in families is often 
impossible due to lack of suitable patient material. For sibpair analysis one can estimate that that at 
least 500-1000 affected sibpairs are needed for such an analysis to be meaningful and significant.92. 
103 Combination of the linkage method with the allele sharing method increases the power of both 
methods. One point of consideration is the combination of populations. If the families from the 
linkage analysis and the affected sibpairs with a single defined phenotype are derived fyom the same 
population, one might expect that in both cases the disease-causing gene or region is the same. 
However, when the families and the sibpairs are from genetically different populations, the disease-
causing gene or region might be quite different, due to the heterogeneity of the populations. 
Association studies in populations are not appropriate for genomic screening for ARM. For a 
candidate gene approach, however, they are usefuL If experimental animal models with ARM or 
with one of its clinical sign exists, they could be useful for studying the pathogenesis of ARM. 
EVIDENCE OF A GENETIC CONTRIBUTION TO AMD 
The evidence for genetic contribution to AMD in humans can be divided into three parts: twin 
studies, research into familial aggregation and segregation analysis, These three provide compelling 
arguments for the role of genetics in AMD, However, they provide only approximate estimates as to 
the complexity and extent of the genetics of AMD. 
Twins are uniquely matched for age and many environmental factors, and therefore fonn a 
fixed sample design provided by nature, Monozygotic twin are genetically identical, while dizygotic 
twins have the genetic similarity of other siblings (on average 50% of their genome is identical). 
Twins have been used to study the role of genetic factors for a large number of different 
phenotypes. The aim of a twin study is to compare similarities and/or differences in phenotype in 
monozygotic and dizygotic twins in order to infer and measure the genetic contribution to their 
phenotype. Greater concordance in monozygotic twins as compared to dizygotic twins argues in 
favor of genetic factors. Discordance in monozygotic twins underscores the role of environmental 
factors, There are relatively few twin studies on AMD. Three case reports exist on identical twins 
having atrophic and/or neovascular macular degeneration as well as one study of nine monozygotic 
twin pairs having a high concordance in either extensive drusen or late stage age-related 
maculopathy.104-106 Klein and co-workers noted that eight of nine monozygotic twin pairs had 
similar fundus appearances. 107 In the ninth pair, one twin had advanced neovascular AMD, while the 
other had large confluent drusen. 
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Meyers et al compared concordance in the presence or absence of any type of ARM in 98 
monozygotic and 38 dizygotic twin pairs, predominantly ascertained through twin organizations,108 
Of all twin pairs affected by ARM, all monozygotic twin pairs were concordant (25/25), while only 
42% of dizygotic pairs were concordant. Selection bias or environmental factors may have played a 
role, but the striking similarity of fundus appearances in each twin pair suggests an increased 
genetic susceptibility in at least some of the patients. 
Although Hutchinson and Tay have observed familial occurence of ARM as early as 1875, 
the disease has not been the subject of extensive genetic investigations,109 Familial studies 
incorporating the late stages of ARM have received comparatively little attention. The aim of a 
family aggregation study is to ascertain whether there is an increased risk of AMD in relatives of 
affected persons as compared to relatives of unaffected individuals or to the general population. 
Hyman et al. were the first to compare on history data the prevalence of ARM among the relatives 
of affected individuals to that among the relatives of a control population.45 They found that a 
positive family history of ARM was reported in 21.6% of affected subjects as compared to 8.6% of 
unaffected controls. Two clinic-based studies found a positive family history of macular disease in 
patients with drusen or pigmentary changes and/or atrophic and neovascular macular degeneration. 
The authors estimated a familial risk of 19,3 and 2,4 respectively.llO,J12 Possible explanations for 
this large difference are the high chance of selection bias with hospital-derived probands, the large 
range of ARM features that were combined, and the use of family history and self-reported 
diagnoses. Klaver et al reported on familial aggregation as part of the Rotterdam Study. JJ3 
Independent of other risk factors they found on examination of cases and controls that the 
prevalence of early and late ARM was significantly higher in relatives of patients with late ARM. 
The lifetime risk ratio of late ARM was 4.2. First-degree relatives of patients with late ARM 
developed early ARM at an increased rate at a relatively young age. The authors concluded that 
almost one fourth of all late ARM cases in the general population may have a genetic component 
and that genetic susceptibility may playa role in determining the onset of disease. 
Observations on familial occurence of ARM indicate a genetic factor in ARM. Francois 
described brothers and sisters in one family who were suffering from senile macular dystrophy.114 
Bradley stated in 1966 that every patient with ARM he had seen had other members of the family 
which were similarly affected. 115 Gass performed a study of 200 patients with macular drusen and 
reported that 10-20% of affected individuals in his study had a positive family history of loss of 
central vision. 116 Klein et at. performed a linkage analysis in a family consisting of 21 family 
members of which 10 were affected.ll7 Recently, we have identified a large family with 22 affected 
individuals with ARM, of which nine with early ARM and 13 with late ARM (see Chapter 6 of this 
thesis). 
Segregation analysis tests explicit models of inheritance on family data. The analytic 
strategy relies heavily on fitting genetic models, along with a few non-genetic ones, and selecting 
the model that best explains the data. So far only one segregation analysis was performed, on data 
from the Beaver Dam Eye study.118 
13 
Chapter 2 Genetics of age-related macu/opathy; a review 
The Beaver Dam population provided evidence for an autosomal dominant trait for AMD with a 
major gene effect and rejected the hypothesis of a random environmental major effect .This 
approach, however, provides no insight into the number of genes involved in all these families. One 
can only conclude from this that within one family the ARM features are quite similar and within 
one family probably caused by a single gene. 
CANDIDATE LOCI AND GENES 
lQ25-1Q31 
Klein et al identified a large family consisting of 21 family members in which ARM was 
segregating as an autosomal dominant trait. 117 In the 10 affected family members ARM was 
manifested by the presence of large, soft, confluent drusen accompanied by varying degrees of 
retinal pigment epithelial degeneration and/or geographic atrophy. After an initial pooled genome-
wide screen, markers from areas most suggestive of shared chromosomal segments were used to 
genotype all potentially informative family members. Genetic analysis of this family produced 
significant evidence for linkage of the disease-gene to a region of approximately 9 cM on 
chromosome lq with a LOD score of 3.0. The disease causing gene in this predominantly dry AMD 
family was located at 1q25-lq31, whereas the ABCR gene, located on Ip2l, was excluded as a 
major gene effect in this family. 
ABCR 
The photoreceptor cell-specific ATP-binding transporter gene (ABCR), located on chromosome 
Ip21, is exclusively expressed in the retina. 119, 110 The ABCR protein is identical to the rim protein 
(RmP), a protein of unknown function, that colocalizes with peripherine/RDS to the rod outer 
segment. 121 ABCR binds ATP, which is consistent with its role as an active transporter. ABCR is 
phosphorylated in response to light, which suggests that it plays a role in photo-transduction. 
Mutations in this gene have been implicated in Stargardt disease, retinitis pigmentosa type 19 and 
cone-rod dystrophy.95~lo2 Recently, Allikmets et al described that variations in ABCR were 
associated with AMD,96 Most of these mutations were found in patients with the dry type of AMD. 
Furthennore, some of these mutations were seen in Stargardt disease as well as in AMD patients. 
After this publication a scientific debate started; main points of discussion were flaws in study 
design, analysis as well as potential misc1assification of the cases. 122, 123 Moreover, results from two 
other studies did not confinn these data,124, 125 Large population studies, animal studies or functional 
ABCR assays are needed to clarify the involvement of ABCR in AMD. Clinical and 
histopathological examination of the recently constructed ABCR knock-our mouse will be helpful. 
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TIMP-3 
The tissue inhibitor of metalloproteinases-3 (TIMP-3) is localized on chromosome 22qI2.1-
q13.2. 126-!28 Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix 
metalloproteinases, which are involved in the synthesis and degradation of extracellular matrix 
molecules, thereby continously remodelling this matrix, 129 Mutations in TIMP-3 were demonstrated 
in affected members of two pedigrees with Sorsby fundus dystrophy. 130. 131 Sorsby fundus dystrophy 
on chromosome 22 is an autosomal dominant macular dystrophy that phenotypically resembles 
AMD. Sorsby fundus dystrophy is characterised by choroidal neovascularisation and macular 
discifonn scarring in younger people. 132-137 The demonstration that Sorsby fundus dystrophy is due 
to mutations in the proteinase inhibitor TIMP3 has potential implications for our understanding of 
the pathophysiology of choroidal neovascularisation and possibly AMD. De la Paz identified 38 
multiplex families with extensive intennediate drusen, any large drusen, geographic atrophy or 
evidence of exudative maculopathy.lJ8 These families were used to perfonn a linkage analysis and 
an association study with the TIMP3 gene. No evidence of linkage or association or both was found 
between AMD and TIMP3 in the families. However, the authors could not exclude the possibility 
that a subset of cases could be caused by TTh1P3 locus, due to several difficulties in evaluating 
candidate genes in complex diseases, such as hetereogeneity, multiple underlying trait loci, 
misc1assification of the phenotype, and potential phenocopies. 
ApOLlPOPROTEIN E 
Apolipoprotein E is the major apolipoprotein of the central nervous system and an important 
regulator of cholesterol and lipid transport. 139. 140 It appears to be associated with neurodegenerative 
diseases, such as Alzheimer disease. Apolipoprotein E mobilizes and redistributes lipids for 
maintenance and repair of neuronal cell membranes, The apolipoprotein E gene (ApoE), located on 
chromosome 19q13.2, is polymorphic, Klaver et a1. performed a genetic association study among 
88 AMD cases and 901 controls derived from a population-based cohort.141 The Apo E4 allele was 
significantly associated with a decreased risk for AMD (Odds ratio 0.43; 95% CI 0.21-0.88). 
Furthennore they investigated whether ApoE is involved in the pathogenesis of AMD, using 
immunoreactivity in 15 AMD and 10 control maculae. They found that ApoE staining was 
consistently present in drusen and basal laminar deposits of post-mortem human AMD maculae. 
Souied et al evaluated ApoE alleles among 116 umelated patients with exudative AMD in one eye 
and hard or soft drusen in the other eye,142 They compared the frequency of these alleles with a 
control population of 168 age- and sex-matched controls. They found a lower frequency of the Apo 
E4 allele in the case group compared to those in the control group (0.073 vs 0.149; p<0.006). 
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OTHER CANDIDATE GENES 
The analysis of candidate genes involves an educated guess about the gene or gene loci that may be 
involved in the disease. Candidate genes for ARM might be selected on the basis of their known 
function(s) as well as known involvement in other fOilllS of inherited retinal degeneration or 
chromosomal position. Potential candidate genes/loci include regions linked to early onset macular 
degeneration with the same phenotypical features of ARM. For example, isolation of the gene 
responsible for Best disease or Stargardt disease may lead to elucidation of a role played by these or 
similar genes in AMD, An overview of candidate genes for AMD is given in Table 2.143. 144 
Table 2. Candidate genes for Age-related maculopathy 
Locus Gene Disease 
Ip31 Rl'E65 Leber congenital amaurosis 
Ip21-p13 ABCR STGD, RP, cone-rod dystrophy, ARM 
Iq2S-31 unknown ARM 
2pI6-p21 DHRD Doyne honeycomb retinal degeneration, Malattia Leventinese 
6p21.2-cen RDS RP, dominant vitelliform MD 
6p21.1 COD3 dominant cone dystrophy 
6q CORD7 dominant cone-rod dystrophy 
6qlI-qiS STGD3 dominant MD, Stargardt like 
6qI4-qI6.2 MCDRI North Carolina MD 
6q25-q26 RCD! retinal cone dystrophy 
7p2I-pI5 CYMD dominant cystoid MD 
8q24? VMDI dominant atypical vitelliform MD 
IOq24 RBP4 recessive RPE degeneration 
llq13 VMD2 dominant MD, Best type 
13q34 STGD2 dominant MD, Stargardt-like 
17p13-pI2 CORD5 dominant cone-rod dystrophy 
17p13.1 CORD6 dominant cone-rod dystrophy 
17q CORD4 dominant cone-rod dystrophy 
18q21.1-q21.3 CORDI cone-rod dystrophy, de Grouchy syndrome 
19q13.2 APOE neurodegenerative diseases, ARM 
19q13.3 CORD2 dominant cone-rod dystrophy 
22qI2.I-q13.2 TIMP3 Sorsby fundus dystrophy 
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With the use of microsatellite markers close to a gene or to a chromosomal locus, given the 
availability of a large family, linkage analysis can be performed in order to dctcnnine whether the 
disease can be caused by the candidate gene. Another technique based on candidate genes is the 
screening for mutations in these genes. In contrast to linkage analysis, in which a disease locus can 
also be used, in candidate gene screening the gene has to be characterized. The nucleotide sequence 
of the gene is compared between in affected patients and unaffected controls. 
CONCLUSIONS AND FUTURE STRATEGIES 
Age-related macular degeneration seems to be partially genetically determined. The late onset ofthe 
disease, the clinical and genetic heterogeneity, and the multifactorial or polygenic inheritance 
complicate the study of the genetic causes of the disease. 145 Given the many problems that can 
hamper genetic dissection of complex traits such as AMD, various different techniques should be 
combined. Futhennore, by narrowing the definition of a disease, it is often possible to work with a 
trait that is more nearly Mendelian in its inheritance pattern and more likely to be homogeneous. 
Four criteria are often used: clinical phenotype, age at onset, family history, and severity. 145, 146 
Another way to improve the prospects for genetic dissection is to focus on specific ethnic groups. 
Population genetic theory and data suggest that there will be greater genetic and allelic homogeneity 
in a more genetically isolated group than in a large, mixed population. 
Which technique should be used to unravel the genetics of ARM depends on the availability 
of patient material. Linkage analysis does not seem to be a promising technique to detect new genes 
involved in ARM, as families with ARM patients in multiple generations are rare, However, when a 
large family with ARM is obtained, linkage analysis is the best method to use, An alternative 
approach is to examine affected sib-pairs, but this requires at this moment at least 500 sibpairs. 
Association studies are important to detennine the contribution of newly identified mutations in 
genes to the occurrence of disease, For this purpose, population-based studies are needed in order to 
overcome referral bias, whereas the problem of survival bias can only be overcome in a follow-up 
setting. As the Human Genome Project advances further in identifying genes, the opportunities for 
mutation analysis in candidate-genes will increase. 
Further research is into the pathogenesis of AMD is necessary in order to eventually develop 
effective therapy. 
METHOD OF LITERATURE SEARCH 
Literature selection for this article was based on a MEDLINE search covering the past 30 years for 
all articles, using key word combinations including age-related macular degeneration, age-related 
maculopathy, genetics, genes, segregation, association, aggregation, twins, macular dystrophy, 
macular degeneration, linkage analysis and (genetic) epidemiology. 
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For review of topics not yet published, literature selection was also based on references from these 
articles and on abstracts from the annual meeting of the Association for Research in Vision and 
Ophthalmology, focusing on the years 1995-1999. We intended to cite a wide range of previous 
work to achieve an objective and balanced review on the topic. Given the broad scope of the topic, 
however, we were forced to limit citations to those articles that were most clinically relevant or 
represented new contributions to the field. 
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-CHAPTER 3-
RISK FACTORS FOR AGE-RELATED MACULAR 
DEGENERATION: 
POOLED FINDINGS FROM THREE CONTINENTS 
ABSTRACT 
Objective: 
Design: 
Participants: 
Main Outcome 
Measures: 
Results: 
Conclusions: 
To assess the prevalence and potential risk factors for late age-related 
macular degeneration (AMD) in tlrree racially similar populations from North 
America, Europe and Australia. 
Combined analysis of population-based eye disease prevalence data. 
14752 participants with gradable photographs from the Beaver Dam Eye 
Study (n~4756), Rotterdam Study (n~6411) and Blue Mountains Eye Study 
(n~3585). 
AMD diagnosis was made from masked grading of stereo macular 
photographs. Final classification of AMD cases was agreed byconsensus 
between study investigators. 
AMD prevalence was strongly age-related. Overall, AMD was present in 
0.2% of the combined population aged 55-64 years, rising to 13% of the 
population aged over 85 years. Prevalence of neovascular AMD (NY) 
increased from 0.17% among subjects aged 55-64 years to 5.8% for those 
aged over 85 years. Prevalence of pure geographic atrophy (GA) increased 
from 0.04% to 4.2% for these age groups. There were no significant gender 
differences in the prevalence of NY or GA. Subjects in the Rotterdam 
population had a significantly lower age and smoking adjusted risk of NY 
than subjects in the Beaver Dam and Blue Mountains populations. Apart 
from age, tobacco smoking was the only risk factor consistently associated 
with any form of AMD in all sites separately, and in pooled analyses over the 
three sites. 
These combined data from racially similar communities across three 
continents provide strong and consistent evidence that tobacco smoking is the 
principal known preventable exposure associated with any form of AMD. 
27 
Chapter 3 Risk factors for AMD: Pooled findings for three continents 
The causes of age-related macular degeneration (AMD), the leading cause of blindness in the 
western world1•S, remain unknown. Tobacco smoking has now been accepted by most investigators 
as an important environmental exposure associated with AMD 6-13, but other risk factors apart from 
age and heredity remain controversial. The situation is further complicated by the repeated 
suggestion that.AJ\1D is not a homogenous diagnosis. Clinicians, pathologists and researchers alike 
refer to two principal late stage lesions (which possibly have different etiologies) that constitute 
AMD14: (I) "geographic atrophy" (GA) and (2) "neovascular AMD" (NY). 
Most studies investigating associations benveen AMD and potential risk factors are hindered 
by the relative infrequence of AMD in the population. This lack of statistical power is further 
aggravated when the investigator examines differences in risk factors benveen the two subtypes of 
AMD. Consequently, some studies have reported their findings as associations with AMD as a 
homogenous identity because they had limited power to make statements about the separate types. 
Three population-based studies conducted in Beaver Dam, Wisconsin 15, in Rotterdam, the 
Netherlands l6 and in the Blue Mountains area, west of Sydney, Australia l7 have provided 
prevalence estimates for GA and NV. These three studies commenced examinations during 1988, 
1990 and 1992, respectively. They used very similar methods, including a standardised technique 
for grading stereoscopic macular photographs, based on the Wisconsin Age-related Macular 
Grading Systeml8 • Although differences in AMD prevalence were found, each study reported 
approximately a 2:1 ratio of NY to GA I5- 17• This matches the recent 5-year incidence report from the 
Beaver Dam Eye Study which found that NY incidence (0.4%) was twice the incidence of GA 
(0.2%)19. Besides using very similar outcome measures, these three sites used similar exposure 
measures for a range of potential risk factors. 
Use of the same grading methods and similar risk factor measures in the three population-
based reports l5- 17 permitted us to pool data on prevalence of, and risk factor associations for AMD 
and its subtypes. We aim in this report to describe the prevalence of NY and GA, and examine 
factors associated with these diagnoses, in the combined popUlation of racially similar subjects who 
attended large population-based epidemiological studies of eye disease in three continents (North 
America, Europe and Australia). 
METHODS 
The Beaver Daru Eye Study (BDES) was conducted during the period 1988-1990 in Beaver Dam, 
Wisconsin and examined 49261 5925 eligible residents aged 43-86 years (response 83.1 %), 
identified in a private census. The Rotterdam Study (RS) was conducted during the period 1990-
1993 in Rotterdam, the Netherlands and examined 7983110,275 eligible residents aged 55-106 years 
(response 77.7%), identified from the municipal registers. The Blue Mountains Eye Study (BMES) 
was conducted during the period 1992-1994 in two postal codes of the Blue Mountains area, 
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west of Sydney, Australia and examined 3654/4433 eligible residents aged 49-97 years (response 
82.4%), identified in a private census. The populations in all three studies were almost entirely 
white, with most subjects in the two non-European sites having a northern European ethnic origin. 
A11 studies employed a similar masked photographic grading technique, based on the Wisconsin 
Age-related Maculopathy Grading System (W ARMGS)'8. The standard W ARMGS grid was 
modified for grading the Rotterdam photographs, because of the difference in magnification 
between the Zeiss 30 0 and Topcon 35 0 photographs. During grading, one of the stereo-photographs 
was overlaid by a grid and the stereo pair was viewed by the grader using a Donaldson stereo-
viewer with 5x magnification. Among participants examined in the three studies, gradable 
photographs of at least one eye were available to assess the presence of AMD for 4756 Beaver Darn 
participants (97.9%), 6411 Rotterdam participants (80.3%) and 3585 Blue Mountains participants 
(98.1 %). These 14,752 subjects provided the data used to assess prevalence of age-related macular 
degeneration. All analyses of risk factors used data from only those subjects aged 55 to 86 years 
(total 12,468 subjects), the common age range for the three sites. The proportion of participants 
with ungradable photographs increased with increasing age. Among subjects aged 55 to 64 years, 
0.9% of Beaver Dam participants, 8.9% of Rotterdam participants and 1.3% of Blue Mountains 
participants had ungradable photographs. For subjects aged 65 to 74 years, corresponding 
proportions were 1.9%, 14.5% and 0.9% and for those aged 75 to 86 years, the proportions were 
6.6%, 27.0% and 3.4%, respectively. All denominator and numerator popUlations for each site 
within this age range are presented in the Tables presenting age-adjusted associations with AMD. 
The two late stage lesions of age-related maculopathy are now tenned ttage-related macular 
degeneration" (AMD), using nomenclature adopted by the International ARM Study Group14. One 
of the two lesions, tenned "geographic atrophy" (GA) by GasslO, was defined as a discrete area of 
retinal depigmentation, at least 175 Jlm in diameter, with a sharp border and visible choroidal 
vessels. The second, more frequent lesion, termed "neovascular AMD" (NV), was defined to 
include serous or hemorrhagic detachment of either the retinal pigment epithelium (RPE) or sensory 
retina, the presence of subretinal or sub-RPE haemorrhage or subretinal fibrous tissue. Eyes in 
which minimal subretinal fibrosis was present as well as widespread sUlTounding atrophy were also 
arbitrarily classified as NY as it was considered that this sign indicated a previous neovascular 
AMD lesion. 
Senior investigators from each of the three sites (RK, PTVMdJ & CCWK, PM) adjudicated all 
cases graded as having NY or GA in either or both eyes. Some AMD cases previously included in 
earlier prevalence reports, including six from each of the Beaver Dam and Blue Mountains Studies 
and four from the Rotterdam Study, were excluded from the analysis after adjudication. This was 
due to either poor photographic quality or because the investigators thought that the signs could 
represent other disease processes2!, such as adult vitellifonn lesions22 , myopic retinopath/3, retinal 
dystrophy or infective/ inflammatory lesions. 
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Four cases initially graded as NV were excluded because their appearance was consistent with the 
drusenoid type of RPE detachment, resulting from confluence of soft drusen material24 • 
Subjects with AMD were classified as having 'Pure GA' when GA was present in one or 
both eyes and neither eye had signs of NY. Subjects were classified as having 'mixed AMD' when 
GA was present in one eye and NY was present in the fellow eye. Subjects with NY as the only 
AMD type present were classified as having 'Pure NY'. If both GA and NY were present in one 
eye, this eye was classified as having NY. 
Data sets from each study site including age, gender, tobacco smoking status and other key 
variables were merged into a combined dataset for statistical analysis using SAS (Statistical 
Analysis System, SAS Institute, Cary, NC)., 
Age-standardized rate ratios and logistic regression were used to assess differences in 
prevalence of AMD and its sub-types between study sites, and to investigate associations with 
major potential risk factors reported for AMD - age, tobacco smoking, gender, high blood pressure 
and other cardiovascular disease diagnoses, cholesterol, iris colour, age at menopause, and hormone 
replacement therapy. All sites included a self-reported history of doctor diagnosis of high blood 
pressure, and measured systemic blood pressure in a clinic. Hypertension was deemed to be present 
if a subject had a history of doctor-diagnosed hypertension or measured systolic blood pressure of 
z160mm Hg, or measured diastolic blood pressure of 290mm Hg. All sites contained similar 
questions about current smoking and ever smoking. Smoking was categorized as current smoker 
(cigarettes, pipe or cigars), ex-smoker and never smoker. All sites measured height and weight. 
Body mass index (BMI) was calculated from measured height and weight using the formula weight 
(kg) divided by height (meters) squared. Categories used included underweight (BMI<20), normal 
BMI (20<BMh25), overweight (25<BMI<30) and obese (BMh30). All sites included self-
reported doctor-diagnosed history of cardiovascular diseases (acute myocardial infarction, angina, 
stroke), self-reported age at menarche and age at menopause, and self-reported history of ever using 
hormone replacement therapy. Iris color was graded before pupil dilatation using illuminated 
standard iris color slides in the Beaver Dam and Blue Mountains sites and using standard color 
prints at the RS site. Cholesterol and HDL-cholesterol were measured from fasting blood at all sites, 
and results converted to mmol/L. Associations between exposures and outcomes were analyzed for 
each site separately, then combined using dummy variables for study site to assess heterogeneity 
across study sites. 
RESULTS 
CHARACTERISTICS OF THE COMBINED POPULA nON 
The combined popUlation with gradable photographs totalled 14,752 participants aged from 43 to 
99 years (mean age 66.0 years), and included 8464 women (57.4%) and 6288 men (42.6%) (Table 
1). 
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Table 1. Prevalence of age-related macular degeneration, including geographic atrophy and neovascular AMD in participants to population-based eye surveys in three continents. 
age group (years) <55 55-64 65-74 75-84 85+ all ages I 
Beaver Dam Eye Study 0=1501 0=1300 0=1243 0=675 0=37 0=4756 
pure geographic atrophy 0 1 (0.08%) 4 (0.32%) 14 (2.07%) 2 (5.41%) 21 (0.44%) 
pure neovascular AMD 0 4 (0.31%) 13 (1.05%) 23 (3.41%) 2 (5.41%) 42 (0.88%) 
mixedAMD 0 0 0 8 (1.19'/0) 1 (2.70%) 9 (0.19%) 
any AMD 0 5 (0.38%) 17 (1.37%) 45 (6.67%) 5 (13.51 %) 72 (1.51%) 
Rotterdam Study Nil n=2340 0=2358 n=1350 n=363 n=6411 
pure geographic atrophy - 1 (0.04%) 8 (0.34%) 17 (1.26%) 16 (4.41%) 42 (0.66%) 
pure neovascular AMD - 2 (0.09%) 7 (0.30%) 23 (1.70%) 14 (3.86%) 46 (0.72%) 
mixedAMD - 0 1 (0.04%) 3 (0.22%) 12 (3.31%) 16 (0.25%) 
anyAMD - 3 (0.13%) 16 (0.68%) 43 (3.19%) 42 (11.57%) 104 (1.62%) 
Blue Mountains Eye Study 0=478 n=1157 1=1198 n=631 0=121 n=3585 
pure geographic atrophy 0 0 2(0.17%) 10 (1.58%) 4 (3.31%) 16 (0.45%) 
pure neovascular AMD 0 2 (0.17%) 6 (0.50%) 21 (3.33%) 14 (11.57%) 43 (1.20%) 
mixedAMD 0 0 0 3 (0.48%) 3(2.48%) 6 (0.17%) 
anyAMD 0 2 (0.17%) 8 (0.67%) 34 (5.39%) 21 (17.36%) 65 (1.81 %) 
Combined 3-site population n=1979 n=4797 0=4799 n=2656 n=521 n=14752 
pure geographic atrophy 0 2 (0.04%) 14 (0.29%) 41 (1.54%) 22 (4.22%) 79 (0.54%) 
pure neovascular AMD 0 8(0.17%) 26 (0.54%) 67 (2.52%) 30 (5.76%) 131 (0.89%) 
mixedAMD 0 0 1 (0.02%) 14 (0.53%) 16 (3.07%) 31 (0.21%) 
anyAMD 0 10(0.21%) 41 (0.85%) 122 (4.59%) 68 (13.05%) 241 (1.63%) 
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The female: male ratio averaged 1.35 for subjects with gradable photos and increased with age. 
Among the Beaver Dam, Rotterdam and Blue Mountains studies, female: male ratios were 1.25, 
1.45 and 1.30, respectively. These ratios reflect age differences between the three studies; in Beaver 
Dam, the mean age was 61.8 years (range 43-86 years), in Rotterdam, the mean age was 69.0 years 
(range 55-99 years),and in the Blue Mountains, the mean age was 66.1 years (range 49-97 years). 
There were 12,468 subjects aged between 55 and 86 years, the age range common to alI study sites. 
PREVALENCE OF AMD 
The distribution of individual and combined AMD lesions by age group and study site is shown in 
Table 1. AMD lesions (NY or GA) were found in 241 participants (1.63% of the combined 
population), including 159 women (1.88%) and 82 (1.30%) men. Seventy-two Beaver Dam 
participants (1.51 %), 104 Rotterdam participants (1.62%) and 65 Blue Mountains participants 
(1.81 %) had AMD lesions. AMD prevalence at each site was strongly age-related, with AMD 
lesions not found in subjects aged less than 55 years, 0.21 % of persons aged 55-64 years, 0.85% of 
persons aged 60-74 years, 4.59% of persons aged 75 to 84 years and 13.05% of persons aged 85 
years or older. 
PREVALENCE OF PURE GA, PURE NY AND MIXED AMD 
The prevalence of Pure GA was 0.44%, 0.66% and 0.45%, for the three sites, respectively. Pure NY 
was almost twice as prevalent as Pure GA in the combined population, with Pure NY prevalence of 
0.88%,0.72% and 1.20%, found for these three sites, respectively. This 2:1 ratio of Pure NY to 
Pure GA was found in Beaver Dam and the Blue Mountains, with the proportion of AMD due to 
GA increasing with age. The ratio of NY to GA, however, was lower in Rotterdam (1.1:1), but the 
relative proportion of GA also increased with age. Mixed AMD was relatively infrequent, and was 
found only in persons older than 74 years, rapidly increasing as a total proportion of all AMD 
(Table 1). The age-specific prevalence for any GA lesion (either Pure GA or Mixed AMD) were 
fairly similar in all study sites. Age-specific prevalence for any GA in the combined population 
(including both Pure GA and Mixed AMD cases) were very similar in men and women (data not 
shown). 
Table 2 shows the risk of AMD and its subtypes in the Blue Mountains and Beaver Dam 
populations relative to the Rotterdam population aged from 55 to 86 years, presented as age and 
smoking adjusted odds ratios. There were significantly lower age-adjusted prevalences for AMD 
and Pure NY lesions in the Rotterdam compared to both the Beaver Dam and Blue Mountains 
populations, for this age group. The age standardised rate ratios were only marginally lower than the 
age-adjusted odds ratios (data not shown). The lower NY prevalence in Rotterdam was almost 
unchanged after adjusting for age and smoking status. The age-adjusted risk for Pure GA was not 
significantly lower in Rotterdam than in Beaver Dam or Blue Mountains. In the combined 
population, there were few differences in age-specific AMD prevalence between men and women 
(data not shown). 
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Table 2. Risk of AMD and its subtypes in the Blue Mountains and Beaver Dam populations relative to the 
Rotterdam population aged 55 to 86 years adjustedfor age and tobacco smoking 
* 
Odds Ratios (95% confidence intervals)* 
Diagnosis AMD (n) Pure Neovascular (n) Pure Geographic Atrophy 
(n) 
t Age-adjusted 
Rotterdam (Index) n=6180 1.00 (74) 1.00 (35) 1.00 (30) 
Blue Mountains n=3034 1.51 (1.04-2.19) (49) 2.20 (1.36-3.54) (34) 0.91 (0.46-1.79) (12) 
Beaver Dam n=3254 2.15 (1.54-3.01) (71) 2.57 (1.63-4.06) (41) 1.54 (0.88-2.71) (21) 
t Age and tsmoking adjusted 
Rotterdam (Index) 1 1 I 
Blue Mountains 1.71 (1.17-2.49) 2.61 (1.60-4.26) 1.01 (0.51-2.00) 
Beaver Dam 2.42 (1.72-3.41) 3.07 (1.92-4.90) 1.68 (0.95-2.98) 
Includmg all subjects from each study aged 55 to 86, excludmg subjects Without smolang data In smokmg the 
smoking-adjusted model 
t Ages from 55 to 86 years (common to all populations), included in the model as a continuous (year) variable 
:j: Smoking status coded as either never, former or current smokers, included in the model as a categorical 
variable. 
FACTORS ASSOCIATED WITH NEOV ASCULAR AMD, GEOGRAPHIC ATROPHY AND ANY AMD 
A total of 12,468 subjects aged 55 to 86 years with gradable retinal photographs were included in 
the merged dataset used to assess associations between AMD and potential risk factors. Tables 3-5 
present associations between a range of exposures and any AMD, Pure GA and Pure NV, 
respectively. The tables show that, apart from age, the only factor that retained a clear association 
with either AMD subtype in all sites and pooled over all sites, was tobacco smoking. Pooled 
analyses showed no significant heterogeneity in the association between tobacco smoking and 
AMD over the study sites. Compared to never smokers, ex-smokers (OR 1.34, CI 0.96-1.87) and 
CUITent smokers (OR 3.11, CI 2.10-4.63) were more likely to have AMD. The association with 
current smoking was stronger with Pure NY (OR 4.55, CI 2.74-7.54) than with Pure GA (OR 2.56, 
CI 1.26-5.20)_ 
33 
1 aOle j. Age-adjusted associations between potential risk/actors and AMD: Odds ratios (95% CI) by location 
Potential Risk Factor Rotterdam nIN* Beaver Dam nIN Blue Mountains nIN All 3 Sites nIN 
Age (Index 55-69) 1.00 9/3593 1.00 1111977 1.00 5/1823 1.00 25/7393 
70-79 4.42 (2.02-9.67) 2111914 6.20 (3.12-12.3) 33/984 8.70 (3.29-23.1) 22/941 6.02 (3.82-9.47) 76/3839 I 
80-86 27.9 (13.5-57.3) 44/673 18.8 (9.26-38.2) 28/294 32.3 02.1-85.9) 22/270 25.3 06.2-39.5) 94/1237 
Gender (Index Female) 74/6180 7213255 49/3034 194/12469 
Male 1.22 (0.75-1.98) 0.86 (0.52-1.42) 0.74 CO.41-1.3§). 0.95 (0.70-1.28) 
Smoking 74/6109 7213253 48/2936 194/12298 
Never (Index) 1.00 1.00 1.00 1.00 
Ex-smoker 1.34 (0.75-2.37) 1.47 (0.87-2.49) 1.21 (0.62-2.36) 1.36 (0.97-1.90) 
Current smoker 3.11 (1.72-5.62) 2.39 (1.144.96) 4.22 (1.90-2.37\ 3.12 (2.10-4.64) 
Body Mass Index 73/6068 7213229 46/2985 191112300 
Underweight (BMI<20) 1.60 (0.53-4.84) 2.93 (1.02-8.38) 1.24 (0.44-3.48) 1.75 (0.95-3.22) 
Normal (Index) 1.00 1.00 1.00 1.00 
Overweight (25<BMI<30) 1.35 (0.79-2.31) 1.08 (0.58-2.01) 1.06 (0.52-2.19) 1.19 (0.85-1.98) 
Obese (BMI,30) 0.85 (0.38-1.86) 1.42 (0.74-2.72) 1.89 (0.82-4.37) 1.30 (0.85-1.98) 
Cardiovascular & Other Disease 
(Index=no disease, normal range) 
Acute myocardial infarction 0.66 (0.28-1.53) 72/6047 0.61 (0.26-1.43) 7113244 1.39 (0.63-3.05) 49/3019 0.81 (0.51-1.30) 192/12310 
Angina 0.59 (0.21-1.64) 74/6114 0.60 (0.28-1.27) 70/3191 1.25 (0.62-2.50) 49/3021 0.78 (0.50-1.23) 193112326 
Stroke 1.04 (0.44-2.46) 74/6081 0.69 (0.27-1.78) 72/3255 1.25 (0.48-3.26) 47/3018 0.94 (0.55-1.60) 193/12354 
Hypertension 0.62 (0.34-1.10) 73/6102 1.65 (0.96-2.82) 72/3254 1.30 (0.73-2.31) 49/3034 1.09 (0.79-1.50) 194112390 
Cholesterol (per mmolll) 0.88 (0.72-1.09) 58/4877 0.94 (0.80-1.21) 72/3246 1.28 (0.98-1.67) 43/2739 1.00 (0.88-1.14) 173/10862 
HDL-cholesterol (per mmoUl) 1.85 (0.95-3.58) 58/4873 0.99 (0.59-1.67) 72/3246 1.36 (0.71-2.59) 43/2740 1.27 (0.90-1.80) 173/10859 
Iris colour 74/6157 7213138 47/2966 193112333 
Grey ·or Blue (Index) 1.00 1.00 1.00 1.00 
Hazel or green 0.42 (0.13-1.37) 0.88 (0.46-1.69) 0.92 (0.45-1.87) 0.79 (0.51-1.22) 
Tan or bro\Vl1 1.00 (0.57-1.78) 1.18 (0.68-2.07\ 0.27 (0.08-0.89\ 0.88 (0.61-1.22) 
Age at menopause 4113442 44/1790 30/1579 11516811 
Age >=45 years (Index) 1.00 1.00 1.00 1.00 
Age <45 ~~ars 1.78 (0.85-3.73) 0.80.(0.39-1.651 1.07 (0.47-2.42) 1.13 (0.73-1.76) 
Time from menarche to 40/3402 44/1782 30/1568 114/6752 
menopause 
<30 years (Index) 1.00 1.00 1.00 1.00 
30-35 years 0.64 (0.25·1.62) 0.94 (0.39-2.23) 0.69 (0.25-1.93) 0.76 (0.45-1.31) 
> 35 years 0.64 (0.28-1.50) 1.06 (0.49-2.29) 0.79 (0.33-1.91) 0.83 (0.51-1.34) 
Hormone Replacement Therapy 45/3495 4511825 3011634 120/6954 
(Index=Never) 1.00 1.00 1.00 1.00 
Ever 0.55 (0.13-2.36\ 0.82 (0.38-1.75\ 0.78 (0.22-2.681 0.77 (0.43-1.39\ 
* n = number of cases of AMD N = number of subjects available for analysis for each potential risk factor 
j'able 4. Age-adjusted associatIOns benveen potential rzskjactors and f'ure (jeographic Atrophy: Udds ratios (95% 0) by location 
Potential Risk Factor Rotterdam nIN* Beaver Dam nIN Blue Mountains nIN All 3 Sites nIN 
Age (Index 55-69) 1.00 6/3590 1.00 3/1969 No cases 0/1823 1.00 917377 
70-79 2.52 (0.88-7.29) 8/1901 6.89 (1.89-25.1) 10/961 Not calculable 6/925 5.25 (2.44-11.3) 24/3787 
80-86 15.2 (5.92-39.0) 16/645 19.7 (5.20-74.8) 81274 Not calculable 6/254 21.8 (10.3-46.0) 30/1173 
Gender (Index Female) 30/6136 2113204 12/2997 63/12337 
Male 1.21 (0.58-2.54) 1.48 (0.62-3.53) 1.98 (0.62-6.33) 1.45 (0.88-2.41) 
Smoking 30/6065 2113202 12/2900 63/12167 
Never (Index) 1.00 1.00 1.00 1.00 
Ex-smoker 1.38 (0.57-3.30) 2.10 (0.85-5.17) 1.14 (0.30-4.31) 1.58 (0.90-2.79) 
Currentsmoker 2.62 (1.03-6.62) 0.77 (0.09-6.34) 5.82 (1.27-26.71) 2.54 (1.25-5.17) 
Body Mass Index 30/6043 21/3178 10/2949 61112170 
Undenveight (BMI<20) 1.15 (0.14-9.36) 2.13 (0.24-18.80) 1.38 (0.14-13.60) 1.45 (0.41-5.06) 
Normal (Index) 1.00 1.00 1.00 1.00 
Overweight (25<BMI<30) 1.56 (0.66-3.66) 1.31 (0.43-3.96) 1.88 (0.41-8.56) 1.52 (0.82-2.82) 
Obese (BMh30) 1.32 (0.43-4.05) 1.41 (0.42-4.70) 2.81 (0.45-17.49) 1.51 (0.72-3.18) 
Cardiovascular & Other Disease 
(Index=no disease, normal range) 
Acute myocardial infarction 0.55 (0.13-2.32) 29/6004 1.16 (0.33-4.00) 20/3193 0.63 (0.08-4.92) 12/2982 0.76 (0.33-1.78) 61112179 
Angina 0.74 (0.17-3.14) 30/6070 0.55 (0.13-2.42) 19/3140 0.38 (0.05-2.94) 1212984 0.56 (0.22-1.42) 61112194 
Stroke 1.42 (0.42-4.77) 30/6037 - 21/3204 0.89 (0.11-7.04) 1212983 0.72 (0.26-2.00) 63/12244 
Hypertension 0.40 (0.14-1.16) 29/6058 2.12 (0.85-5.33) 21/3203 0.40 (0.11-1.50) 12/2997 0.72 (0.39-1.32) 62/12258 
Cholesterol (per nunol/l) 0.85 (0.61-1.17) 24/4843 0.70 (0.47-1.04) 2113195 1.19 (0.69-2.03) 10/2706 0.84 (0.67-1.06) 55/10744 
HDL-Cholesterol (per nunolll) 2.39 (1.02-5.59) 24/4839 0.81 (0.30-2.16) 2113194 0.82 (0.19-3.46) 1012708 1.25 (0.68-2.32) 55/10741 
Iris colour 30/6113 21/3159 12/2931 63/12203 
Grey or Blue (Index) 1.00 1.00 1.00 1.00 
Hazel or green 0.33 (0.05-2.48) 0.80 (0.26-2.49) 1.02 (0.26-3.90) 0.71 (0.33-1.54) 
Tan or brown 0.89 (0.36-2.19) 0.70 (0.22-2.16) - 0.64 (0.32-1.29) 
Age at menopause 17/3418 11/1757 511554 33/6729 
Age >=45 years (Index) 1.00 1.00 1.00 1.00 
Age <45 years 2.32 (0.80-6.75) 0.26 CO.03-2.05) 0.63 (0.07-5.75) 1.00 (0.43-2.33) 
Time from menarche to menopause 13/3379 11/1749 5/1543 33/6671 
<30 years (Index) 1.00 1.00 1.00 1.00 
30-35 years 0.75 (021-2.63) 3.96 (0.46-34.13) 0.88 (0.05-14.31) 1.31 (0.49-3.49) 
> 35 years 0.38 (0.11-1.39) 2.43 (0.28-20.91) 1.51 (0.15-14.81) 0.85 (0.32-2.24) 
Hormone Replacement Therapy 18/3468 11/1791 5/1609 34/6868 
(Index=Never) 0.78 (0.10-6.11) 1.07 (0.27-4.18) 1.77 (0.19-16.82) 1.12 (0.42-3.03) 
Ever 
* n = number of cases of Pure GA N = number of subjects (excluding subjects with Pure NY) available for analysis for each potential risk factor 
Table 5. Age-adjusted associations between potential risk factors and Pure Neovascular AMD : Odds ratios (95% CI) by location 
Potential Risk Factor Rotterdam Beaver Dam ruN Blue Mountains All 3 Sites ruN 
Age (Index 55-69) 1.00 1.00 1.00 1.00 1617384 
(Index:no disease, normal range) 
Acute myocardial infarction 
Angina 
Stroke 
Hypertension 
Cholesterol (per mmolll) 
HDL-Cholesterol per mmol!l) 
Grey or Blue (Index) 
Hazel or green 
<30 years (Index) 
30-35 years 
0.70 (0.21-2.30) 
0.63 (0.15-2.63) 
0.71 (0.17-3.02) 
0.83 (0.38-1.79) 
0.88 (0.65-1.19) 
3416009 
3516075 
3516042 
3516064 
2712846 
1.84 (0.39-1.59) 
1.00 
0.83 (0.37-1.89) 
0.53 (0.16-1.74) 
0.68 (0.26-1.75) 
1.09 (0.38-3.14) 
1.77 (0.89-3.52) 
1.13 (0.88-1.47) 
4113214 
4113162 
4113224 
4113223 
4213216 
1.84 (0.78-4.34) 3413004 
1.81 (0.85-8.87) 3413006 
1.46 (0.50-4.29) 3313004 
2.02 (1.00-4.08) 3413019 
1.24 (0.90-1.70) 3012726 
1.00 
1.54 (0.97-2.44) 
1.72 (0.81-3.65) 
1.00 
0.94 (0.60-1.49) 
0.94 (0.52-1.70) 
1.03 (0.60-1.75) 
1.07 (0.55-2.08) 
1.48 (0.99-2.22) 
1.01 (0.91-1.27) 
1.00 
109112227 
110112243 
109112270 
110112306 
99110788 
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DISCUSSION 
This report represents the first attempt to combine unit data from distinct population-based eye 
studies to investigate AMD and its two subtypes, Strengths of this pooled study include its large 
sample size and the relatively similar photographic documentation performed at each of the three 
sites. A further strength is the use of a similar grading protocol by graders who had all spent periods 
of training at the Fundus Photograph Reading Center in Wisconsin. Also, the inclusion of all cases 
classified as having AMD was agreed by investigators from each of the three studies. Potential 
weaknesses, however, include differences in the response rates for the three studies and site 
differences in photographic technique. Although graders from each of the three sites spent a period 
of training in Wisconsin, there remains a possibility that systematic grading differences in the three 
studies could have occurred. It seems likely that this would tend to reduce rather than increase 
apparent AMD prevalence, as all identified AMD cases had to be agreed by senior investigators 
from the three sites before inclusion. 
The exposures considered here were collected using similar, but not identical, interviewer~ 
administered questionnaires, and coded in a similar manner at each study site. Despite apparent 
similarities in data collection and coding, there may remain some differential exposure 
measurement error between sites, either through differences in question wording, interviewer 
administration or cultural factors. However, it is more likely that non-differential measurement error 
will be present at all sites, leading to a bias toward the null - that is leading to less likelihood of 
finding a significant association between exposures and AMD. 
The combined study has shown relatively similar age-specific prevalence for both Pure NV 
and any AMD separately in the Beaver Darn and Blue Mountains Studies. However, substantially 
lower age-specific NY (and consequently AMD) prevalences were found in the Rotterdam Study. 
Adjusting for gender and the major known potential confounders, including tobacco smoking, did 
not greatly alter these differences in popUlation risks. Is this site difference real or could it be due to 
systematic grading differences or to differences in subject selection? There were some differences in 
the photographic documentation perfoIDled, principally the use of Topcon 35 0 stereo-photographs 
in Rotterdam while Zeiss 30 0 stereo-photographs were taken at the other two sites. It does not seem 
very likely, however, that this magnification difference or other variations in photographic 
technique or quality among those with gJ'adable photographs could explain such a large age-specific 
difference in prevalence. In eyes with reduced photo quality, a small GA lesion might be expected 
to be less easy to grade than a small neovascular AMD lesion. However, a similar 2:1 ratio of Pure 
NY to Pure GA was found in Rotterdam as well as in the other two sites, which suggests that 
reduced photo quality in one site may not have caused the difference observed. 
However, there remains a distinct possibility that the lower proportion of Rotterdam 
participants who had gradable photographs in at least one eye could have contributed to the 
differences found. 
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In the overall 55 to 86 year age group, 84% of Rotterdam participants had gradable photographs, 
compared with 97.4% of Beaver Dam participants and 98.2% of Blue Mountains participants. A 
lower prevalence of AMD in the Rotterdam population could have been fmmd if subjects with 
AMD were less likely than others in the community to have gradable photographs. 
Differences in the population ascertainment methods (use of Municipal Registers in Rotterdam 
compared with conduct of a private door~to-door census in Beaver Darn and Blue Mountains) Of in 
the participation rate (78% in Rotterdam, compared to 83% in Beaver Dam and 82% in Blue 
Mountains) could also have contributed to the differences in prevalence. For example, some nOll-
responders may have decided not to attend the respective Eye Studies because they had previously 
been diagnosed with eye diseases such as AMD and were already under regular ophthalmic review. 
FurthemlOre, different health care systems or attitudes toward health may explain differences in 
prevalence. Individuals with disease may be more likely to participate in one country (because they 
believe they can derive benefit from the examination) than in another (because they are more 
fatalistic about their disease). The results could then be biased by location due to differential 
response by cases with ARM. However, such differential non-response seems unlikely to explain a 
large difference given the similar pUblicity provided to each local community and to local 
ophthalmologists about the emphasis on AMD by each study. 
If the lower age-specific AMD prevalence found in the Rotterdam Study, however, is real, it 
is possible that there may be differences in the prevalence of major non-genetic (environmental) 
AMD risk factors found between the three communities. The only environmental exposure clearly 
associated with any AMD type in both the individual and pooled studies was tobacco smoking. 
However, smoking is unlikely to have contributed to the differences in prevalence of AMD found, 
as after including smoking status in the multivariate models, the associated risk for AMD by study 
site was almost unchanged. The three-fold risk of any AMD associated with current smoking in the 
pooled data was relatively similar across the three sites, with statistical1y significant odds ratios of 
2.4, 3.1 and 4.2 for the Beaver Dam, Rotterdam and Blue Mountains populations, respectively. The 
magnitude of risk with current smoking was higher in the pooled dataset for NY (OR 4.6) compared 
to GA (OR 2.6), although site differences existed in the subset analyses for GA. These findings 
reflect the consistency of recent population-based and cohort study reports that have linked 
smoking to AMD6,8,25,12,26,\3,27,28.29, 
The finding of only one significaut association with AMD in the pooled data (tobacco 
smoking) may be due to relatively greater measurement enor associated with the other exposures 
investigated (medical history etc). The higher measurement error would lead to larger biases toward 
the null, decreasing the possibility of finding true associations with AMD. However, this seems 
unlikely to have been a sufficiently large bias to affect the associations examined. 
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There was no meaningful heterogeneity across study strata for the association between tobacco 
smoking and any type of AMD, strengthening the argument that this is likely to be a true 
association. For some exposures, a weak consistent non-significant association across study sites 
and in the pooled estimate was found. For example, for the variable 'ever having taken honnone 
replacement therapy', site-specific associations ranged from 0.55 to 0.84 and the pooled estimate 
was 0.78 (0.44-1.41), but was clearly not statistically significant. For other exposures, the pooled 
estimates were virtually uninterpretable because estimates of association were relatively 
heterogeneous across sites. For either of these reasons, the pooled analyses could not provide any 
evidence to support any consistent association between AMD and any of the remaining exposures 
investigated. There were no apparent differences in risk factors for NY compared to GA. 
Another possible explanation for the differences in AMD prevalence observed between 
study sites may be differences in sunlight exposure, as suggested in the Chesapeake Bay Watermen 
Study30. However, recent findings from a large Australian case-control study failed to confinn a 
sunlight exposure link with AMD31. A major criticism of many studies of the association between 
sunlight exposure and AMD is the difficulty in quantifying exposure differences among people all 
living in the same location. The three sites are likely to have considerable differences in sun 
exposure due to their latitude differences (52°in Rotterdam, 44 ° in Beaver Dam and 34 ° in the Blue 
Mountains), as well as differences in average cloud COVer. If sun exposure were important, then this 
could explain a lower AMD prevalence in the Rotterdam participants, but does not explain the 
lower prevalence in the Blue Mountains, latitude 34 0 compared to Beaver Dam, latitude 44 0. There 
may be a threshold effect for snnlight exposure, which may be more strongly associated with NV 
than GA lesions. This could explain why Beaver Dam and Blue Mountains had higher prevalence 
than Rotterdam while there was no trend across the three sites with latitude. A possible confounder 
could be individual exposure through lifestyle and occupation. As Beaver Dam is a rural 
community, participants may be more likely to have worked in outdoors jobs, or spent leisure time 
outdoors, than in the other two populations. This may have decreased prevalence differences 
between the Blue Mountains and Beaver Dam populations. 
Current research indicates there may be a strong genetic basis for AMD32, with high familial 
aggregation rates reported from a number of recent studies33 -35 • Thus, a third possibility is that there 
may be important genetic differences between the three communities. For example, there may be 
differences in the prevalence of key mutations in AMD candidate genes. Given the influence of 
genetic and enviromnental factors found for this disease, it is also possible that there may be 
differences between the communities in the extent of gene-environment interaction. 
In summary, despite the differences found in age-specific prevalence for AMD and its 
subtypes between study sites, the characteristics of the lesions and the ratio of NY to GA were 
relatively consistent across study sites in three continents. The NY differences in age-specific 
prevalence found comparing Rotterdam with the other two sites carmot readily be explained by 
differences in age, sex, smoking status, grading or diagnostic procedures. 
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The differential effects of latitude and genetic factors also could not be ruled out as possible 
explanations for the observed differences in age-specific prevalence of neovascular AMD lesions. 
These pooled data from racially similar communities across three continents provide strong 
and consistent evidence that tobacco smoking is the principal known preventable exposure 
associated with any fann of AMD. The findings support further health advocacy approaches to 
reduce the tobacco smoking rate, even among the older elderly in our popUlation, and also support 
research to identify possible candidate genes that may predispose to age-related macular 
degeneration. 
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- CHAPTER4 -
INCIDENCE AND PROGRESSION OF AGE-RELATED 
MACULOPATHY; THE ROTTERDAM STUDY 
ABSTRACT 
Objective; 
Design: 
Participants: 
Methods: 
Main Outcome 
Measures: 
Results: 
Conclusions: 
To describe the incidence of late stages of age-related maculopathy (ARM) 
and the progression of earlier stages, and to Shlrly the hierarchy of fundus 
features that determine progression. 
Population-based prospective cohort study. 
A population of 4948 subjects aged 55 years and older living in Rotterdam, 
the Netherlands, was studied to detennine the incidence of neovascular and 
atrophic macular degeneration (AMD). A subgroup of 1244 subjects was 
studied for progression of early stages of ARM. 
At baseline and at 2-year follow-up, fundus transparencies were graded for 
features of age-related maculopathy using the International Classification 
System. ARM was stratified in four exclusive stages according to type of 
drusen and presence of pigmentary irregularities. 
AMD,ARM 
The overall 2-year cumulative incidence of AMD was 0.2%, increasing to 
1.2% in subjects of 85 years and older. Of the early stages, 22% showed 
progression to a more severe stage. Most important predictors for progression 
were more than 10% ofmacu!ar area covered by drusen (OR 5.7, 95% CI 2.5, 
13.1), presence of depignlentation (OR 5.0, 95% CI 3.2, 7.8), and 
hyperpigmentation (OR 3.1, 95% CI 2.0, 4.7). 
The incidence of AMD appears to be lower in the Netherlands than in the 
United States. Progression of early stages occurs in a distinct pattern at a 
stable rate with a large area of drusen and pigmentary changes as most 
important predictors. 
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INTRODUCTION 
A large number of studies have shown that ARM is a frequent eye disorder in the elderly, !.J and that 
its end stages are the most important cause of irreversible blindness in the Western world. 4-6 The 
design of most of the epidemiologic studies has been cross-sectional, and they have provided 
information on disease prevalence and prevalence associations, 
In etiologic research, however, incidence is commonly preferred over prevalence. Incidence 
represents the actual disease occurrence, and risk analyses based on incident cases are more 
suggestive of a causal relation, since exposures are measured before the onset of disease. Incidence 
data of ARM would improve the knowledge on the etiology, early development and progression of 
this disease. At present, these data are still scarce.7.8 
The purpose of this study was to describe the incidence and progression of ARlv1 in the 
population-based Rotterdam Study in the Netherlands. We studied the incidence of the late stages of 
ARlv1 in the entire cohort, and investigated progression of early features in specific subgroups. 
Furthennore, we aimed to assess the prognostic value of the various fundus features that are 
associated with ARM. 
SUBJECTS AND METHODS 
POPULATION 
The Rotterdam Study is a population-based prospective cohort study conducted in a suburb of 
Rotterdam, the Netherlands, in which chronic ophthalmologic, neurologic, cardiovascular, and 
locomotor as well as endocrine disorders are investigated. Methods used to identify and describe the 
population have appeared in previous reports. 2,9 Baseline interview and screening examinations took 
place from 1990 to mid 1993, follow up examinations from mid 1993 to the end of 1994. 
Of 10,275 eligible subjects aged 55 years and older living in Rotterdam, 7983 (78%) agreed 
to participate in the baseline phase of the study. Gradable fundus transparencies were available on 
6411 subjects, of whom 104 (1.6%) subjects were diagnosed with the late stages of ARM, i.e., 
atrophic or neovascular AMD. This resulted in a cohort of 6307 subjects at risk for incident AMD. 
PROCEDURES AND DEFIN1TrONS 
The screening for presence of ARlv1 followed the same protocol at baseline and at follow up. 
Procedures have been described in detail elsewhere.2,9 In brief, during the screening eye 
examination 35° color transparencies were taken of the macular area (Topcon TRV-50VT fundus 
camera, Topcon Optical Company, Tokyo, Japan). The diagnosis of ARM features was based on 
grading of fundus transparencies according to the International Classification System,10 in which all 
features of age-related maculopathy are called ARM and the two late stages are called AMD. At 
baseline, fundus transparencies of the entire cohort were graded in a detailed manner to identify all 
features of ARM. At follow up, all fundus transparencies of the entire cohort were graded for 
presence of atrophic or neovascular AMD. 
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Table 1. Stratification of ARM in exclusive stages of severity 
Stage of 
Criteria 
No. No. No. selected 
ARM at baseline at follow-u(! for analysis 
No ARM No ARM features or only drusen s 6311m 4025 3234 327 
Stage 1 (i) Soft distinct drusen 1465 1144 331 
(ii) Pigmentary irregularities 332 248 248 
Stage 2 (i) Soft indistinct drusen or reticular drusen 180 121 121 
Soft distinct drusen with pigmentary 
(ii) irregularities 222 170 170 
83 
Soft indistinct or reticular drusen with 
Stage 3 pigmentary irregularities 83 47 47 
Stage 4 Atrophic or neovascular macular 104 54 0 
degeneration (AMD) 
To assess the incidence and progression of early ARM features, ARM at baseline was stratified in 
four exclusive stages of disease (Table 1). On the basis of previous findings/,g·l1,12 we assumed 
more clinical severity and a higher risk of development of AMD with each successive stage. The 
stage classification of a subject was based on the eye with the most severe stage of ARM. ARM 
stages I (i) and (ii) were considered one stage of clinical severity, as were stages 2 (i) and (ii). For 
reasons of feasibility and efficiency, only a randomly selected subset of subjects with no ARM or 
ARM stage I (i) at baseline underwent detailed grading of early ARM features at follow up. Of all 
other stages, the entire group of subjects with gradable fundus transparencies underwent detailed 
grading at follow up. 
Incidence of an ARM lesion was defined as absence of this particular lesion within the grid 
area of either eye at baseline and presence ofthis lesion in at least one eye at follow up. Progression 
of ARM was defined as an increase in one or more stages of ARM; no progression was defined as 
no change or a decrease in stage. 
STATISTICAL METHODS 
Subjects with AMD at baseline were excluded from the incidence and progression analyses. The 
age-specific incidence rate of AMD was obtained per lO-year age-categories by dividing the 
number of incident cases by the number of person-years per age-category. The latter was calculated 
by summing each participant's contribution of follow up time per age-category. Confidence 
intervals of incidence rates were calculated with the exact method. Age at follow up was regarded as 
age at onset of incident AMD. Cumulative incidences were calculated from the incidence rates with 
the fonnula 
Cf(t)=l-e -fR't 
where CI is the cumulative incidence over a period of t years, IR is the incidence rate, and e is the 
constant 2.71828, the base of the natural logarithm. Progression of early ARM stages was studied 
by logistic regression analysis with age, gender, baseline stage of ARM and duration of the follow 
up period fixed in the model. In an initial 'univariate' analysis with these fixed factors the predictive 
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power of drusen size and location, proportion of macular grid area covered by drusen, most frequent 
drusen size, largest drusen size, drusen confluence, presence and area of hyperpigmentation, and 
presence and area of depigmentation was evaluated. Statistical interaction between macular area of 
drusen and hyper- or depigmentation, between hyper- and depigmentation, and between area of 
drusen and drusen confluence was studied by entering the product term of these factors in the 
model. Fundus features or product terms with a significant odds ratio entered a subsequent 
'multivariate' analysis to determine the independence and magnitude of prognostic factors. 
RESULTS 
INCIDENCE OF AMD 
Of the 6307 subjects at risk for incident AMD, 5442 (86%) participated ill the 2-year follow up 
phase of the Rotterdam Study. Of the non-participants, 326 subjects had died before follow up, and 
539 (10%) subjects refused to participate in any follow up examination. Of subjects that consented 
to follow up, 5097 participated in the fe-screening eye examination. Gradable fundus transparencies 
of at least one eye were present in 4948 subjects, 78% (4948/6307) of the total number of subjects 
at risk for incident AMD, and these subjects were included in the incidence analyses. They 
significantly differed from other eligibles by age, but, after adjustment for age, not by stage of ARM 
at baseline (table 2). 
Table 2. Baseline characteristics of subjects at risk of incident AMD 
Eligible subjects (n 6307) 
Characteristics 
In analysisl Not in analysis1 
(0=4948) (0=1359) 
Age at baseline (%) 
55 - 64 
43.2 24.3 
Y 
65 -74 38.1 30.2 
Y 
75 - 84 
16.2 33 
Y 
85 + Y 2.5 12.5 
Gender (% womenl 58.5 61.3 
Institutionalized (%)3 4.4 10.2 
ARM at baseline (%)3 
Stage 
29.1 28.4 
Stage 6.5 5.9 
2 
Stage 
3 
l.l 2.1 
I subjects with gradable fundus transparencies 
2 deceased, non-participants, and subjects with ungradable fundus transparencies 
3 adjusted for age 
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p 
<0.001 
0.Q7 
<0.001 
0.15 
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After an average follow up period of 2.0 (SD 0.6) years, there were 11 cases with incident AMD. Of 
those, 5 cases were identified with atrophic AMD and 6 with neovascular AMD. Given a total of 
9833 person-years, the overall incidence of AMD was 1.1 per 1000 person-years (2-yr cumulative 
incidence 0.22%). The incidence increased with age (table 3). Figure 1 shows the estimated 5-year 
cumulative incidence risk in the Rotterdam Study in comparison with the two other population-
based incidence studies that report 5-year incidences. 
Table 3. Age-specific incidence rates per 1000 person-years 
incidences (%) of AMD in the Rotterdam Study 
Age-grou(! Person-:y:ears N Rate 95%CI 
55-64 3530 0 0 (0,0.001) 
65-74 4009 1 0.2 (0.01,1.4) 
75-84 1955 8 4.1 (1.8,8.1) 
85+ 338 2 5.9 (0.7,21.4) 
Total 9833 11 1.1 (0.6. 2.0) 
C!l 
u 16 c 
C!l 14 
" '0 12 
.S 
C!l 10 IIIDWaterman .~-m~ 
-~ 
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::l 6 o Rotterdam E 
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Figure 4. Comparison of the estimated age-specific 5-year cumulative 
incidence of AMD in the Rotterdam Study with the 5-year 
cumulative incidences in the Waterman study 7 and in the 
Beaver Dam Eye Study'. 
and 2-year cumulative 
2-:y:r incidence 
0 
0.05 
0.82 
1.18 
0.22 
Overall, there were no statistically significant gender differences in incidence of AMD. Among the 
2078 men, the overall incidence was 1.00 per 1000 person-years (2-yr cumulative incidence 0.2%), 
while among the 2870 women, the overall incidence was 1.20 per 1000 person-years (2-yr incidence 
0.2%, p ~ 0.24, adjusted for age and follow up time). 
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Incident AMD was strongly associated with stage of ARM at baseline. Neither ARM stage 0 nor 
stage 1 progressed to incident AMD. ARM stage 2 gave rise to 3 subjects with incident atrophic 
AMD and 4 with incident neovascular AMD. For this stage, the overall incidence rate of AMD was 
12.1 per 1000 person-years (2-year cumulative incidence 2.4%), ranging from 4.0 per 1000 person 
years (2-yr incidence 0.8%) in subjects under 65 years to 35.4 per 1000 person-years (2-yr incidence 
6.8%) in subjects aged 85 years and older. Stage 3 at baseline gave rise to 2 subjects with incident 
atrophic AMD and 2 with incident neovascular AMD. For stage 3, the total incidence rate of AMD 
was 37.6 per 1000 person-years (2-yr incidence 7.4%), and the age-category in which this occurred 
was 74-85 years. 
Of the 31 subjects with AMD in only one eye at baseline, 3 subjects with atrophic AMD and 
4 subjects with neovascular AMD developed incident AMD in the second eye at 2-yr follow up. 
This resulted in an incidence rate of 109.9 per 1000 person-years (2-yr cumulative incidence 19.7%) 
for involvement of the second eye. The 3 subjects with unilateral atrophic AMD at baseline 
developed the same type of ANID in the second eye. Of the 4 subjects with neovascular AMD, 2 
developed neovascular AMD and 2 developed atrophic AMD in the other eye. The baseline ARM 
stages of the second eye were stage 2 (3 subjects) and stage 3 (4 subjects). 
PROGRESSION OF EARLY STAGES 
Of the 1244 subjects who were selected for the early ARM progression analyses, 315 subjects 
progressed to a more severe stage of ARM. For the total cohort, this implied a 2-year cumulative 
progression rate of21.5%. Table 4 shows the incidence rates of the various stages of ARM at follow 
up. Age was associated with progression: adjusted for gender, follow up time and baseline stage of 
ARM, the odds ratio of progression for age per year was 1.02 (95% CI 1.00, 1.03). Gender was not 
associated with progression: the odds ratio for women versus men was 0.98 (95% CI 0.75, 1.27; 
adjusted for age, follow up time and baseline stage of ARM). 
Table 4. Incidence rates a/the various stages of ARA1per 1000 person-years based on 2-year 
follow-up (2-yr cumulative incidences, %) 
Stage of ARM 
Follow-up Follow-up Follow-up Follow-up 
Sta e J Sta e 2 Sta e 3 Sta e 4 
Baseline Stage 0 112.8 (20%) 4.5 (1%) 0 0 
Baseline Stage J 112.5 (20%) 15.8 (3%) 0 
Baseline Stage 2 119.9 (21 %) 11.7 (2%) 
Baseline Sta e 3 37.6 7% 
In the 'univariate' analysis of prognostic factors, macular area covered by drusen, presence and area 
of hyperpigmentation, presence and area of depigmentation, nnmber of small drusen « 63pm), 
number of large drusen (:dZ5,um), and drusen confluence were significantly associated with 
progression (data not shown). 
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In the 'multivariate' analysis with these significant factors in the model, all factors except number 
of large drusen (L125,um) remained statistically significant. A large area of drusen was the most 
important predictor of ARM progression; the odds ratio for> 1 0% of macular area covered by 
drusen was 5.8 (95% CI 2.5, 13.3) (table 5). The other important independent predictors were 
presence of depigmentation, hyperpigmentation, 10 or more small drusen, and at least 10% drusen 
confluence. Area of depigmentation with a total diameter larger than 500 I"m had a higher odds 
ratio than did smaller area's (odds ratio for area >500 I"m versus area <175 I"m 4.61 (95% CI 2.48, 
8.56), indicating that larger area's of depigmentation were more prognostic than smaller area's. 
Area's ofhyperpigmentation larger than 125 I"m did not have higher odds ratio's than area's of 125 
,urn or smaller, indicating that larger area's of hyperpigmentation were not of additional prognostic 
value. We found no evidence for statistical interaction between area of drusen and pigmentary 
irregularities, between hyper- and depigmentation, or between area and confluence of drusen (data 
not shown). 
Table 5, Fundus features prognostic for progression of ARM 
Fundus feature OR (95% elf 
Total drusen area ::::10% of grid 
Presence of depigmentation 
Presence ofhyperpigmentation 
::::10 small drusen (.:s..63flm) 
:::10% drusen confluence 
5.78 (2.52, 13.30) 
4.95 (3.15, 7.79) 
3.09 (2.02, 4.72) 
3.01 (1.90, 5.11) 
2.77 (1.81, 4.24) 
• based on a model which included these factors, plus age, baseline stage of ARM, and 
duration of follow-up period 
DISCUSSION 
In the Rotterdam Study, the incidence of ARM's late stage, AMD, was 1.12 per 1000 persons per 
year for subjects aged 55 years and over. The incidence of AMD showed a strong relation with age 
and increased to 5.9 per 1000 persons per year for those aged 85 years and older. The incidence of 
AMD in the contralateral eye of subjects already affected by unilateral AMD was 109.9 per 1000 
persons per year. The most predictive stage for development of incident AMD was ARM stage 3, 
which comprises the presence of either soft indistinct or reticular drusen, or soft drusen with 
pigmentary irregularities. Progression of early stages of ARM occurred in a very distinct pattern at a 
rate of 22% in two years. Most important predictors for progression were more than 10% of macular 
area covered by drusen, presence of depigmentation, and presence ofhyperpigmentation. 
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A good estimate of the incidence of AMD requires the [al1ew up of many subjects over a long 
period of time, because the occurrence of this clinical end stage is relatively infrequent. 
A large study popUlation with a significant number of elderly is one of the strengths of the 
Rotterdam Study. However, the length of the follow up period was not long, and the number of 
subj ects who developed incident AMD was low. Therefore, our estimated incidence rate of AMD is 
rather imprecise. On the other hand, the short follow up period was a benefit for the study of the 
progression of early ARM stages. This enabled us to register small changes and to determine a 
pattern of progression, which may add to the understanding of the natural course of this disease. 
The age-specific incidences of AMD appeared to be lower in the Rotterdam Study than in 
the Waterman Study or the Beaver Darn Eye Study (figure 1).,·8 The American studies took place in 
different parts of the United States, but show incidences within the same range. We estimated a 
five-year cumulative incidence by extrapolation of our data in order to allow for a meaningful 
comparison, and in coming years we will be able to evaluate whether this estimation is correct. 
Nevertheless, the difference seems considerable, consistent over the age-groups, and in agreement 
with earlier reports indicating global differences in the occurrence of MID. Comparison of 
prevalence data from the Beaver Darn Eye Study, the Blue Mountain Eye Study, and the Rotterdam 
Study learned that the prevalence of AMD was highest in the United States and lowest in the 
Netherlands. I"3 The three studies used very similar methods of diagnosis based on fundus 
photography, which makes it less likely that the differences were a result of observation bias. 
Known risk factors such as smoking and cardiovascular disease did not explain the differences 
("Smith et aI, submitted"), and it remains a key point of interest to identify the environmental and 
genetic factors that are accountable. 
The 2-year incidence of AMD in the fellow eye in subjects with unilateral AMD was 20%, 
and the type of AMD was not necessarily concordant with the first eye. The Beaver Dam Eye Study 
found a 5-year incidence of22% for the second eye,S considerably lower than the Rotterdam Study. 
The lower age-range in Beaver Dam may well account for this difference. Our data are in line with 
clinic-based studies reporting the rate of fellow eye involvement. The majOlity of these studies 
focussed on patients with neovascular AMD, and estimates for annual second eye incidence mostly 
ranged from 4 to 10%,11.13-17 although annual incidences up to 15% have been published. IS 
Comparison of rates is generally hampered by differences in age, duration of disease, and diagnosis, 
and long-time follow up of large, well-defined study groups will be needed to provide valid and 
precise estimates. 
An important objective of the study was to describe the progression of early features of 
ARM. For long it has been known that soft drusen and pigmentary changes are precursor lesions 
that increase the risk of geographic atrophy and neovascular AMD. 7,s,11-20 After appearing, drusen 
and pigmentary changes may regress and disappear, but generally this is a result of appearance of 
more severe lesions.7,s In the Rotterdam Study. we did not focus on individual fundus lesions. To 
enhance clinical relevance, we preferred to study progression of AR1Vl in exclusive stages of 
disease. 
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We stratified early features of ARM in three stages based on type of drusen and presence of 
pigmentary changes, the factors which have been shown to be strong predictors for the development 
of AMD.7,8,11,12 The ranking of the stages proved to be in accordance with clinical severity: the risk 
of AMD increased from virtually no risk for stages 0 and 1, to a 2-year risk of 2.4% and 7.4% for 
stages 2 and 3, respectively. An interesting finding was that progression predominantly occurred to 
only one more advanced stage at a rate of approximately 20% in 2 years for the earliest stages (table 
4). Progression from stage 3 to 4 was slower and occurred at a rate of 7% in 2 years. Some subjects 
progressed fast and skipped one stage, but no subjects skipped more than one stage in the 2 years of 
follow up. These findings add to the view that development of ARM is not a random occurrence of 
events, but rather seems to follow a well-defined pattern at a stable rate. 
In accordance with others,8 we found that a large area of the macula covered by drusen and 
pigmentary irregularities were important and independent predictors of ARM progression. Other 
predictors were number of small drusen, and drusen confluence. The number of intermediate (64-
124Jlm) and large drusen (> l25Jlm) did not have additional predictive power, neither did location 
of drusen. Although small drusen « 63Jlm) are not considered an ARM feature in the International 
Classification System, our data indicate that more than 10 small drusen are predictive of ARM 
progression independent of other features. This is consistent with findings from the Watennan 
Study' and the Beaver Dam Eye Study,' which both reported that many small drusen increased the 
risk of large and soft indistinct drusen, but not of AMD. From our results and those of others we 
conclude that progression of early ARM appears to follow a distinct pattern. A large number of 
small hard drusen or isolated pigmentary changes may indicate the very early start of ARM. Then 
soft drusen emerge. Subsequently, at a stable rate, mUltiple drusen of various sizes appear and 
become confluent, the total area increases and some of the drusen become soft indistinct. Next, the 
appearance of pigmentary changes at this stage, especially large areas of depigmentation, then 
further increases the risk of AMD. Subretinal neovascularization or development of geographic 
atrophy denote the etiologic end stage of ARM. 
In conclusion, the 2-year incidence of AMD in the Rotterdaru Study was 2.2 per 1000 
subjects. Our data provide further evidence that ARM is a progressive disease with a distinct 
temporal sequence of events ultimately ending in AMD. 
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HETEROGENEITY OF THE GENETIC RISK IN 
AGE-RELATED MACULOPATHY 
A POPULATION-BASED FAMILIAL RISK STUDY 
ABSTRACT 
Earlier studies demonstrated an increased risk of age-related maculopathy (ARM) for first degree 
relatives of affected sUbjects. We aimed to assess whether the genetic risk of ARM shows 
heterogeneity among families. Case (n~64) and control (n~lOO) probands were selected from the 
population-based Rotterdam Study, and first degree relatives were examined for diagnosis of ARM 
by fundus photography. A family score method was used to estimate a risk for each family taking 
into account the risk of disease expected on the basis of age. Families of cases were at a higher risk 
of ARM than families of controls. Familial heterogeneity of risk was suggested within the case 
families, with 17% at low familial risk of ARM, 14% at intermediate risk, and 3% at high familial 
risk of ARM. Family score was significantly associated with late ARM (,81.28, 95% CI 0.56-1.99; 
adjusted for age, sex, and smoking). Our results show that the risk of ARM varies among families, 
and suggest that only a small fraction of all ARM is due to a strong genetic component. 
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INTRODUCTION 
Age-related maculopathy (ARM) is a frequent eye disease among elderly, and currently the leading 
cause of blindness in developed countries,l It has been well recognized that genetic factors are 
implicated in the etiology of the disease/,3 However, estimates of the magnitude of this component 
vary significantly among family studies. In two clinical studies, the reported odds ratios for first 
degree relatives of cases were 2.4 to 19.3, respectively.4,) In a segregation analysis based on sibships 
from the Beaver Darn Eye study, it was suggested that - 56% of the total ARM variability was 
compatible with a single major gene. 6 In our previous familial aggregation study based on probands 
from the Rotterdam Study, we estimated that the life time relative risk of end stage ARM was 4.2 
(95% CI 2.6, 6.8) for first degree relatives of cases, and calculated that genetic factors attributed 
-23% to all end stage ARM in the population.' 
Although the ABCR and APOE genes have been associated with ARM, the knowledge of 
the disease-causing genes is limited.s-ll Most former study designs regarded ARM families as a 
genetically homogeneous population. In a complex disease such as ARM, that is rather unlikely. 
Presumably, there are families with a strong genetic susceptibility, as well as families with only a 
mild or no genetic risk, and the relative frequencies of these families will determine the overall 
magnitude. Knowledge of the specific familial risks will enhance genetic research, but is also 
particularly relevant for clinical counseling of individual families. 
In this report, we further explored the data of our previous familial aggregation study with 
the aim to detect variation in risk among ARM families. For each family, we calculated a risk score 
based on observed and expected number of affected relatives using demographic and epidemiologic 
data. 12 This methodology allowed us to discriminate between high and low risk families, to 
investigate their frequencies, and to assess the association with risk of ARM. 
SUBJECTS AND METHODS 
COLLECTION OF FAMILIES 
Design of the familial aggregation study and methods of data collection have been described 
previously.7,13 In brief, all probands were identified from the baseline phase of the Rotterdam Study; 
case probands (n=101) were all subjects with atrophic or neovascular macular degeneration, and 
control probands (n~154) were a randomly selected sample of study subjects who did not have any 
soft drusen (:::63Jlm), nor any atrophic or neovascular macular degeneration, Probands differed in 
age (cases mean age 81.9 years vs controls 76.7 years, P<O.OOI), but not in gender (cases 63% 
women vs controls 56% women, age-adjusted P ~ 0.64). Genealogical data of the last five 
generations were obtained from probands; no probands were genealogically linked. First degree 
relatives were subsequently invited for a screening examination at a research center or at home. 
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DIAGNOSIS OF ARM 
The ophthalmologic examination included fundus photography of a 20" and 35 0 macular field with 
a stereoscopic (Topcon TRC-SS2 stereoscopic fundus camera, Topcon Optical Company, Tokyo, 
Japan) and monoscopic camera (Topcon TRV-50VT fundus camera, Topcon Optical Company, 
Tokyo, Japan). Subjects who were examined at home were photographed with a portablc camera 
(35 0 field, Kowa RC-2 fundus camera, Kowa Corporation LTD, Tokyo, Japan). Fundus 
transparencies were graded for presence of ARM features in a masked fashion according to the 
International Classification System, identical to the protocol that was used for probands,l4 ARM 
was stratified in two stages of disease, Early ARM was defined as the presence of either soft distinct 
drusen with pigmentary changes or the presence of soft indistinct or reticular drusen. Late ARM 
was defined as the presence of atrophic (geographic atrophy) or neovascular AMD. 
Table 1. Age-specific prevalence (%) of ARM in the baseline phase 
of the Rotterdam Study, 1989-1993 
Age (years) Early ARM Late ARM Total ARM 
55 - 59 2.2 0.2 2.4 
60 - 64 3.2 0.1 3.3 
65 - 69 5.1 0.5 5.6 
70 -74 10.6 0.8 11.4 
75 -79 12.6 1.7 14.3 
80 - 84 14.8 6.5 21.3 
85 - 89 18.5 9.2 27.7 
90+ 21.2 17.7 38.9 
STA TISTICAL ANALYSES 
Age-specific prevalences of ARM were determined from the baseline phase of the Rotterdam 
Study," and they served as the expected outcome of ARM for each relative (Table I). For each 
family, the expected number (Ei) of affected relatives for the ith family was compared to the 
observed number (0) to give a family score (FS) for this family as 
FS= 0-£ , , 
This formula was originally described by Houwing-Duistermaat et aI, who showed that this 
equation may well be used for incorporation of family data into logistic regression models. 15 .16 
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Since our study population consisted of first degree relatives only, no weights reflecting the distance 
between relative and proband were used. 
Family scores were subsequently stratified in four risk groups: no increased risk (FS < 0.5); 
low risk (0.5 " FS < 1); intermediate risk (l <; FS < 2); and high lisk (FS ;> 2).15.17 The relative 
frequencies of these strata were calculated. The risk of late ARM was estimated for family score 
using linear regression analysis, adjusting for the possible confounding effect of age, sex, and 
smoking. An additional analysis was performed to study the potential confounding effect of 
atherosclerosis. 
Table 2. General characteristics of the study population 
Total no. of relatives 
No. of siblings 
Mean age of siblings, yrs, ± SD 
% women among siblings 
No. of offspring 
mean age of offspring, yrs, ± SD 
Case families 
(n ~ 64) 
186 
73 
76.0 ± 8.7 
55 
113 
53.7 ± 10,4· 
% women among offspring 43 
• p < .001 for the difference with relatives of controls 
RESULTS 
Control families 
(n~lOO) 
343 
142 
75,4 ± 9,4 
59 
201 
48.8 ± 8.9 
46 
Of case probands. 87 (86%) subjects consented to participation in the familial aggregation study; of 
control probands, 135 (88%) responded. Of the relatives of cases. 73 (85%) siblings and 113(86%) 
children responded. Of relatives of controls. these responses were 142 (80%) and 201(81 %). 
respectively. This resulted in 64 case families and 100 control families available for the family 
score analyses. Table 2 shows the distribution of age, gender, and composition of the families; table 
3 shows the number of affected and unaffected relatives among case and control families. 
Table 3. Frequency of ARM among first degree relatives per family· 
No. of relatives Case families t 
affected (n = 64) 
o 41 (64) 
1 14 (22) 
2 7(11) 
* 2m 
• Frequencies in numbers (percentages) 
Control families 
(n ~ 100) 
84 (84) 
15 (15) 
0(0) 
1 (1) 
t The difference in distribution of number of affected relatives between cases and controls was statistically significant, 
peoO.002 
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The individual family scores ranged from -0.7 to 3.5 in the entire study group. Table 4 shows the 
distribution of family scores among cases and controls. The family scores in the case families varied 
fyom -0.4 to 2.9. Nine families had a family score between 1 and 2, and 2 families had a score above 
2. No significant differences were found in distribution of low, medium, and high family scores 
between probands with atrophic and neovascular AMD (data not shown). The family scores in the 
control families ranged from -0.7 and 1.0 with an outlier of one family with a family score of 3.5. 
This family consisted of 12 relatives of whom four were affected. Two affecteds were relatively 
young and largely detennined this high family score. The control proband in question was stiIl 
unaffected at the time of this analysis. 
Table 4. Distribution of Family Scores in risk categories among case and control families' 
Family score 
FS < 0.5 no risk 
O.5s:FS<1 
1 s; FS < 2 
FS~ 2 
low risk 
intennediate risk 
high risk 
• Frequencies in numbers (percentages) 
Case families t Control families 
(n~64) (n~100) 
43 (67) 90 (90) 
1 t (17) 9 (9) 
8 (13) 0(0) 
2 (3) 1 (1) 
t The difference in distribution of FS between cases and controls was statistically significant, P=0.0004 
In Figure lA and IB, the relative frequencies of family scores are plotted. Among cases, there was a 
peak around zero with a skewed tail composed of families with higher than expected rates of ARM. 
Among controls, the distribution of the family scores was, apart from the outlier, centered around O. 
Case Families (n= 64) 
iijtl~~7Z~Z~/~\~\\;~~,~~~~~~~~~ 
-2 0 2 4 6 
Family Score 
Figure 5a Frequency (%) of family scores in 
case families 
B Control Families (n=100) 
Family Score 
Figure Ib Frequency (%) offamily scores 
in control families 
The risk P of'late ARM for family score was 1.10 (95% CI 0.43, 1.76) when adjusting for age, and 
gender, and increased to 1.28 (95% CI 0.55, 1.99) when adjusting for age, sex, and smoking. 
Additional adjustment for atherosclerosis did not alter the risk estimate. 
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DISCUSSION 
In this analysis, we demonstrated familial heterogeneity of the ARM risk using a family score 
method. 15- 17 The majority of ARM families did not appear to have higher frequencies of disease than 
expected on the basis of their age distribution. However, 17% of families had a low increased risk, 
13% an intermediate risk, and 3% a high of disease, much higher than expected by the age 
distribution of the family members. Subjects with an intermediate or high familial risk were at least 
30 times more likely to be affected than subjects with no excess familial risk. This increased risk 
could not be explained by the known risk factors smoking and atherosclerosis; on the contrary, the 
risk accrued when the effect ofthese factors was taken into account. 
There are several advantages of the design and method of analysis in this study. In contrast 
to former familial risk analyses of ARM which pooled relatives from different families, we used a 
family score method which regarded individual families as the unit of analysis. This strategy was 
developed earlier by Houwing·Duistennaat et al. for modeling family history in logistic regression 
models. 15,16 Per family, the observed number of affected relatives was compared with the expected 
number, resulting in a risk estimate for each family. An important benefit is that this allowed for 
discrimination of risk in families from the same proband group. Other strengths of the study include 
the calculation of the expected ARM risk from the age-specific prevalences in the Rotterdam Study, 
the same source population as where the case and control probands originated from. Moreover, 
relatives were actually examined and photographed, and the diagnostic criteria for observed and 
expected number of affected relatives, as well as for cases and controls, were identical. 
Among the limitations of our approach is, that consideration of the family as the unit of 
analysis created loss of statistical power. Due to the relatively small number of families, and the 
small number of relatives per family, statistical significance between familial risk strata could not 
be achieved. For the total number of families that were studied, we were limited by the frequency of 
ARM in the Rotterdam Study. Increasing the number of families and expanding the study 
popUlation with second degree relatives would improve precision of the risk estimates. Another 
issue is that our study popUlation consisted of prevalent rather than incident cases, leading to 
misclassification of family scores due to an unknown age of onset. On the other hand, this will be 
the situation encountered in clinical practice, By using age-adjusted prevalences for the expected 
number of relatives, we adjusted the excess familial risk for age at examination. Finally, control 
probands were younger than case probands, and may have harbored 'subclinical' familial cases of 
ARM. The effect of this potential misclassification appeared to be small, for observed family scores 
were close to the expected score among the control families. The exception was one family with 
four relatives affected, of whom the proband was stiIl unaffected at the age of 87 years. 
Given these considerations, what can be learned from this study? Our data emphasize that 
ARM is a genetically complex disorder with a large variation in the contribution of the genetic 
component in families. Although possible, it is unlikely that all our data are explained by variation 
of one single major gene.6 
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Presumably, a strong genetic factor with a Mendelian inheritance determines the risk in high risk 
families, and this proportion of families appears to be small. In the other families, multiple 
etiologies may be involved: some genetic, some environmental, and most likely a combination of 
these. 
In summary, the results of this analysis complement our earlier findings. 7 We confirmed that 
families of cases are at an increased risk of ARM, but now demonstrated that the variation in 
familial risk is large. The classification of ARM families into high, intermediate, and low risk 
families may allow molecular genetic studies to focus on the appropriate risk groups in the search 
for disease-causing genes. 
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-CHAPTER 6-
GENOMIC SCREENING FOR AGE-RELATED 
MACULOPATHY IN AN ISOLATED POPULATION 
INTRODUCTION 
Age-related maculopathy (ARM) is a complex eye disorder, affecting people of 55 years and over. 
In this disease the central part of the retina, the macula, is affected, which causes central vision 
loss.I~3 Age-related maculopathy consists of a variety of signs varying from drusen to the endstages 
of the disease, geographic atrophy and neovascular macular degeneration.4-6 
Among the many risk factors potentially involved in ARM, aging and smoking were 
consistently found in studies. 7 Other factors possibly involved are cardiovascular factors, light, 
cataract surgery and diet. 8,9 For the involvement of genetic factors many clues can be found in the 
literature. Twin studies, familial aggregation and segregation analyses provided evidence for 
involvement of genetic risk factors in ARM. 10-17 Many genes are possible candidate genes for ARM. 
Candidate genes may be selected from their known function, chromosomal position, and their 
known involvement in other forms of inherited retinal degeneration such as Stargardt disease or 
Sorsby fundus dystrophy .. 
Recently, in a large pedigree, in which 10 family members were affected with early or late 
ARM, Klein et a1. demonstrated linkage between ARM and a locus on chromsome lq25-31. 18 
Others have showed in association studies that ARM is possibly caused by mutations in the ABCR 
gene on chromsome 1 p.19 The ABCR gene is a photoreceptor cell specific ATP-binding transporter 
gene and known to be involved in Stargardt disease. Another candidate gene for ARM, the TIMP-3 
gene, known to be involved in Sorsby fundus dystrophy, is located on chromosome 22.20 La paz and 
co-workers excluded TIMP~3 gene to be involved in 38 small families with ARM, it still remains a 
candidate gene for ARM.21 
One of the major problems in studies of the genetics in ARM is the late onset of the disease. 
The parents are usually deceased while the younger generation does not have the disease on a 
clinical level yet. Individuals available for studies are usually limited to sibships. It is therefore very 
difficult to find families, which are large enough for linkage analysis. Umelated individuals, which 
are generally easier to recruit than large families, are used in association studies. However, in 
genetically hetereogenous disorders, such as ARM, multiple mutations in different genes may exist 
or different mutations in one gene derived from several founders may exist. Association studies are 
therefore not appropriate for genomic screening. Genetically isolated populations are more suitable 
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for such studies, because the number of founders is limited. The number of mutations cosegregating 
in such a community is therefore more limited. 
In the current study we have examined individuals derived from a genetically isolated 
population and we have identified a large family with ARM within this population. The aim of this 
study is to identifY genetic loci which are involved in ARM in this family and to exclude other 
candidate loci. 
MATERIALS AND METHODS 
The study was approved by the medical ethical committee of the Academic Medical Center in 
Amsterdam, the Netherlands. Informed consent was obtained from all study participants. 
Individuals with ARM from a genetically isolated community in the Netherlands were ascertained 
through the registers of ophthalmologists and general practitioners. Ophthalmological examination 
was performed at their homes. A questionnaire was used for indicating general health problems. 
The ophthalmologic examination included fundus photography of 35' macular field with a 
portable camera (35 0 field, Kowa RC-2 fundus camera, Kowa Corporation LTD, Tokyo, Japan). 
Fundus transparencies were graded for presence of ARM features in a masked fashion according to 
the International Classification System.6 ARM was stratified in two stages of disease. Early ARM 
was defined as the presence of either soft distinct drusen with pigmentary changes or the presence 
of soft indistinct or reticular drusen. Late ARM was defined as the presence of atrophic (geographic 
atrophy, GA) of neovascular AMD (NMD). 
Genealogical data were obtained at least six generations back. From all individuals blood 
samples were taken from which DNA was isolated by standard techniques as described elsewhere.22 
If applicable, blood was also taken from spouses as well as children, to construct the haplotypes of 
the cases and the controls. A genome wide screening with 400 polymorphic markers was performed 
in this pedigree. The markers were equally spaced with an interval of maximum 10 cM between 
them. 
From all cases the haplotypes were manually constructed, using the alleles from the children 
and spouses if available. The reconstructed chromosomes of the spouses were used as controls. In 
the control group 40 chromosomes (18 were tested, 22 reconstructed) could be used for analysis, for 
the case group 44 chromosomes were identified. Of the 22 affected individuals in this pedigree, the 
haplotypes of 15 individuals could be constructed by the use of the alleles of children and spouses. 
The alleles of the other 7 individuals were known, although no haplotype could be constructed. 
From all 400 markers the alleles were counted among the cases and controls. Chi-squares were 
calculated to detect differences in allele distribution between the case and control group. The Chi· 
squares and p-values were calculated and if it was significant an odds ratio was calculated. 
Genotypic data were also analysed with a likelihood ratio statistic which tests whether a single 
marker allele is overrepresented on chromosomes of patients as compared to control chromosomes 
(Terwilliger, 1995).23 This approach rests on the assumption that many of the patients may share a 
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chromosomal segment surrounding a shared disease mutation, which may have been inherited from 
a single common ancestor. Given the availability of genotypic data of spouses and offspring for 
many of the patients we employed an implementation of this test stat istic which can appropriately 
analyse data for related individuals, as described in Escamilla et al.24 
The first aim of this study was to examine three candidate loci, chromosome lq, ABCR and 
TIMP3 gene, to see whether excess sharing of marker alleles andlor haplotypes in any of these 
regions could be observed in patients. For the locus on chromosome lq we used marker D1S2655, 
for the ABCR gene markers DIS435, DIS495, D1S221 and DIS252, and for the TIMP3 gene on 
chromosome 22 markers D22S280, D22S283 , and D22S274 ITom the genomic screening marker set 
together with some additional markers in these regions (see Table 1). 
For the purpose of this initial study, haplotypes of these three regions were constructed in 
the cases. When more than one solution was found for a haplotype construct, all solutions were 
taken in the analysis . The haplotypes were compared with each other, to investigate a possible 
region of haplotype sharing, as well as to investigate cosegration ofa haplotype with a specific faml 
for ARM (early ARM, GA or NMD). 
The second aim of this study is to identify regions of mterest, in which a disease-causing 
gene might be localised. Markers which revealed a chi-square with a p-value lower than 0.05 with 
both (manually and by the method of Terwilliger) methods were identified as regions of interest. 
This part of the data analysis is sti ll in progress. 
RESULTS 
In total 23 affected individuals with ARM" were ascertained in this genetically isolated community. 
All but one individual were genealogically linked to each other, constructing a large five generation 
fanli ly with multiple loops (figure I). One individual wi th ARM was excluded from this study. He 
was not born in this conununity, but lived here since he had married. Of the 22 affected individuals 
in this family, nine individuals were diagnosed with early ARM. The end stages of ARM, age-
related macular degeneration (AMD), were seen in 13 individuals, of whom 38,4 % were diagnosed 
with geographic atrophy and 61,5% were diagnosed with neovascular macular degeneration. In this 
study 45 % of the affected individuals were male. The age at examination varied from 66 years to 
91 years of age. 
An overview of the chi-squares, p-values and markers of the three candidate loci is given in 
Tablel. For the region of the lq locus, markers DIS2655 revealed a chi-square of 0.06. The ABCR 
gene markers DIS435, DIS495, DIS221 , and D1S252 showed a chi-square ofO.30, 1.32, 1.09 and 
0.30 respectively. The TIMP-3 gene markers D22S280, D22S283, and D22S274 showed a chi-
square of 0.46, 0.84 and 1.36 respectively. 
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Figure 1. Pedigree of the affected individuals with ARM in a genetically isolated community. 
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Table I 171e three candidate regions examined in the initial study 
Marker eM from pter Chi-square p-value 
Chromosome 1 q DIS2625 215.6 0.16 >I< 0.7 
DIS412 216.8 0.13 * 0.7 
DIS413 219.4 2.48* 0.1 
DIS2655 22l.l 0.06 0.4 
AlleR gene DIS435 128.9 0.3 0.3 
DIS206 137.6 0.69 >I< 0.4 
DlS495 146 1.32 0.2 
DIS221 146.7 1.09 0.2 
DlS252 155.1 0.3 0.3 
TIMP3 gene D22S280 25.9 0.46 0.3 
D22S283 33.4 0.84 0.2 
D22S274 45.5 1.36 0.1 
* based on manually constructed haplotypes. 
The haplotypes did not cosegregate with a specific type of ARM (early ARM, geographic atrophy 
or neovascular macular degeneration) and no haplotype sharing region was fotmd in these three 
candidate regions (data not shown). 
The genomic screening revealed five regions of interest, in which the p-value was in both 
methods lower than 0.05. The highest chi-square of these two methods is noted, The chi-squares of 
these five regions were 4.5 (p ~ 0.03), 4.6 (p~O.03), 7.2 (p~O.007), 8.9 (p~ 0.003) and 11.4 (p ~ 
0.0003). In these regions more markers will be tested in the near future. This wi11lead to exclusion 
of some regions and probably one or two regions will be candidate regions for the disease-causing 
gene in this family. 
DISCUSSION 
In the cunent study we identified a large family with ARM (early and late ARM) in a genetic 
isolate. A genetically isolated population has several advantages; for the use of allele sharing 
methods the number of founders is limited and therefore the mutations in genes or the number of 
genes are most likely also limited. For this study not only an allele sharing method was performed, 
the nucleair families makes it possible to perform linkage analysis. The combination of these two 
approaches provides maximum infonnation and statistical power. 
In the first part of this study we focussed on three candidate genes I loci, chromosome I q, 
the ABCR gene and TIMP-3 gene. Although significant proof was given by Klein et al." for the 
involvement of chromosome lq in a large pedigree with ARM, no evidence of involvement of this 
locus was found in our pedigree. Equally no involvement of ABCR or TIMP-3 was found. 
However, we can not exclude these loci to be involved in ARM, since heterogeneity and multiple 
67 
Chapter 6 Genomic screening for AMD in an isolated population 
underlying trait loci are difficulties in evaluating candidate genes in complex diseases, such as 
ARM. 
The five regions of interest which have been identified will be investigated in the near 
future. Additional markers in these regions will be tested and analysed. The allele sharing method 
will be combined with a linkage analysis in closely related affected individuals to obtain maximum 
statistical power. One might expect that some regions will be excluded and that one or two regions 
will remain of great interest as possible loci for disease-causing gene. 
In the evaluation of the results obtained in a genome wide search for association, a statistical 
correction should be applied for the fact that manu markers are tested. Each additional marker tested 
will lead to an increase in the overall possibility to obtain one or more false-positive signals. There 
is debate over the exact threshold that shoul be applied in a genome wide search for association of 
the results to accepted as conclusive evidence. In this study we have not included any corrections 
for multiple testing, yet. The current results should be reviewed more as an attempt to identify and 
rank-order promising chromosomal regions that deserve futher analysis, than as a final proof for one 
or more ARM loci. As has been suggested before, many genes may be involved in ARM. A gene in 
a pedigree from a genetically isolated popUlation may be involved in just a very small proportion of 
the general popUlation. However, it could provide clues to the pathogenesis of ARM. 
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-CHAPTER 7-
SORSBY FUNDUS DYSTROPHY WITHOUT MUTATION 
INTIMP-3 GENE 
ABSTRACT 
Aims: 
Methods: 
Results: 
To examine a large family with an autosomal dominant fundus dystrophy and to 
investigate whether mutations in TTMP-3 gene were involved. 
A large family of 58 individuals with an autosomal dominant fundus dystrophy was 
ophthalmologically examined. A DNA linkage analysis of the region 22qI2.I-qI3.2 
was perfonned. The TTh1.P-3 gene was screened for mutations in all five exons. 
In this large family 15 individuals were affected, all other individuals were found to 
be clinically unaffected. Pi sci form flecks in the midperiphery and drusen-like 
deposits were the most typical ophthalmological finding in this family and were 
encountered from the fifth decade on. Chorioretinal atrophy and neovascularization 
with disciform lesions characterized the disease from the sixth decade on. Linkage 
analysis, in an affected-only analysis, showed a maximum positive lodscore of 3.94 
at 8 = 0.0 with marker D22S283. No mutations possibly causing Sorsby fundu s 
dystrophy were found in either the exonic sequences, the promotor region or 3'UTR. 
Conclusion: The family in this pedigree is suffering from an autosomal dominant fundus 
dystrophy, which is most likely Sorsby fundus dystrophy. Although, in the linkage 
analysis significant positive lodscores were found with the region 22q I2. I-qI3.2, no 
causative mutations could be identified in the five exons and the promotor region of 
the TIMP-3 gene. 
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INTRODUCTION 
Sorsby fundus dystrophy (SFD) is an autosomal dominant disorder in which patients lose central 
vision during the 4th or 5th decade of life. I Monogenic macuiopathies such as Sorsby fundus 
dystrophy have been suggested as a possible mendelian model for the study of the genetically 
complex age-related macular degeneration (AMD). However, de la Paz ex1cuded TIMP-3 gene in 
38 families as a candidate gene for AMD.2 Age-related macular degeneration is the leading cause of 
permanent visual impairment among the elderly in western countries, affecting over 10% of the 
population aged 75 years and over.3.4 Identification of molecular defects underlying AMD has been 
hampered by the late onset of symptoms, as well as the clinical heterogeneity commonly observed 
in the disorder. 
Sorsby described five families with a fundus dystrophy that occurred in several generations 
in a dominant pedigree pattern.' The dystrophy became manifest at about the age of 40 years, the 
earliest manifestations were colour vision deficits and abnormal yellow-white deposits; followed by 
a central macular lesion with oedema, heamorrhage and exudates. In the subsequent years, atrophy 
with pigmentation of the central area and extension peripherally occurred. The choroidal vessels 
became exposed and appeared somewhat sclerotic. Within about 35 years after onset the entire 
fundus was involved. The choroidal vessels disappeared by this stage and the tenninal picture was 
one of extensive choroidal atrophy. Night blindness was not a consistent feature. 
Sorsby's observations have been extended in the descendants of the original families with 
SFD.'-7 Also a genealogic link between these families and an Australian family with SFD have been 
reported. 8•9 Hamilton et a1. described a seven-generation family with Sorsby fundus dystrophy.lO 
Later on, Weber et al. demonstrated linkage of the SFD locus with DNA markers on chromosome 
22q l3-qter." 
In parallel, Apte et al. isolated a novel gene-member of the tissue inhibitors of 
metalloproteinases (TIMPs), TIMP-3 and localized it to human chromosome 22qI2.I-q13.2. 12 
TIMPs are natural inhibitors of matrix metalloproteinases (MMPs), which are involved in the 
synthesis and degradation of extracellular matrix (ECM) molecules, thereby remodeling the ECM 
continously. Because of the colocalization ofTIMP-3 and SFD on chromosome 22 and its pivotal 
physiological role in extracellular matrix remodeling, Weber et al. studied TIMP-3 as a candidate 
gene for SFD. 13 Point mutations in the TIMP-3 gene were demonstrated in affected members of two 
SFD pedigrees. These mutations predicted disruption of the tertiary structure and thus the functional 
properties of the mature protein. 
In this study we examined a large family with a Sorsby fundus dystrophy to investigate 
whether mutations in TIMP-3 gene were involved. 
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Figure 1 
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Pedigree of the family with Sorsby fundus dystrophy. Males are represented by 
squares and females are represented by circles; blackened symbols represent 
individuals with Sorsby fundus dystrophy, un blackened symbols represent normal 
individuals. * represents the individuals who were clinically examined and used for 
linkage analysis. 
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MATERIALS AND METHODS 
A large family of 58 individuals with a five generation history of fundus dystrophy was examined 
by indirect ophthalmoscopy (see figure I). followed by fluorescein and indocyaninc green 
angiography in case fundus lesions were found on ophthalmoscopy. No genealogic link between 
this family and the families originally described by Sorsby was established. Informed consent was 
obtained from all individuals. Two patients (III,! 0 and III,16) were examined in our department 
respectively in 1975 and 1984; both died before the start of this study. Another individual (IV,55) 
died during the examination period and underwent 'only ophthahnoscopy. 
Blood samples from all individuals were obtained. Standard techniques were used to extract 
DNA, and peR and CA-repeats analyses were performed as described elsewhere. 14 
Because the clinical data were compatible with a dominant mode of inheritance and the diagnosis of 
Sorsby fundus dystrophy was proposed after examination of the individuals, a linkage analysis of 
the region 22qI2.1-qI3.2 was performed. Markers D22S275, D22S304, D22S283 and D22S274 
were used to perform a linkage analysis.II,IS We have used an affected only analysis. The data were 
analyzed with the programme package LINKAGE, version 5.1. Two point Z values were calculated 
with the programme LINKMAP. The fixed order and genetic distances were set as follows 
D22S275- 0.07 - D22S304 - 0.066 - D22S283 - 0.168 - D22S274. 
Because the linkage analysis showed significant evidence for linkage to this region, the 
TIMP-3 gene was screened for mutations. The likely position of TIMP-3 is between D22S275 and 
D22S283. We used all sequence and primers available to us of the TIMP-3 gene for the single 
strand conformational polymorphism (SSCP) of the five exons, the promotor region and 3'UTR."·17 
SSCP analyses were performed as described elsewhere. l8 Also further analysis with sequencing, 
using the dideoxy nucleotide chain termination method, was performed. The direct sequences of 
exon 5 could not be analysed beyond doubt, therefore PCR amplified exon 5 fragments were cloned 
into the peR vector (Invitrogen) using TA cloning kit and multiple colonies were sequenced. 
RESULTS 
In this large family 15 individuals were affected with SFD, all other individuals were found to be 
unaffected. However, some of the healthy individuals have not reached the age of 40 years and 
therefore they might develop the disease in the coming years. 
Figure 2 
fLPisciform flecks at the posterior pole (patient IV,57). !z,. Flecks nasally to the papil (patient 
IV,57). ~ Drusen-like deposits (patient IV, 62). 4. Extensive chorioretinal atrophy (patient IV,12)L 
Choroidal neo-vascularization with haemorrhages and exudation (patient IV, 9). i Disciform lesion 
with fibrotic reaction extending/or outside the macula (patient IIl,16 OD). gPlsciform flecks at the 
arcades, atrophic patches surrounding the macula (patient III, 16 OS). 
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Figure 3 
Q. Patient IV, 12 at the age 0/60 years: OS visual acuity 0.2, notice atrophy 0/ the eapillmy. 
b. Same patient (IV, 12) at the age 0/63: OS visual acuity decreased to LP due to involvement o/Ihe 
macula by the chorioeapillary atrophy. 
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The ophthalmological data of these 15 paticnts are summarized in Table I. The results of two 
patients, who were examined in the past, are also included in this table. The affected individuals had 
a large variety of ophthalmoscopical findings (see figure 2-3). 
Table 1. Ophthalmological data of patients with Sorsby fimdus dystrophy. 
Patient Age Piscifonn 
(years) flecks 
ODS 
III, 10 60 + 
1II,16 74 np 
111,20 78 -
m,23 60 
1II,25 80 -
IV,4 50 + 
1V,9 556063 + 
-
-
IV, 10 55 + 
IV,12 4.7c+07 np 
+ 
+ 
-
1V,14 52 + 
IV,28 4960 -
-
IV,31 59 + 
IV,52 59 + 
IV,55 54 
IV,57 35 + 
1V,62 48 
V,27 31 -
op - not performed 
M = macular discifonn lesion 
P = peripapiUary discifonn lesion 
RD = retinal detachment 
IV,62 OD amblyopia 
Drusen-like Chorioretinal Disciform 
deposits atrophy lesion 
ODS ODS OD OS 
+ + - P 
np + M -
+ M M 
+ - M M 
+ + -
- -
+ + - M 
+ + P M 
+ + RD M 
- -
np - - -
+ + P -
+ + P -
- + P 
+ - - -
+ M -
+ + M -
+ - -
+ - -
+ - - -
- - -
+ - -
+ - -
Visual acuity 
OD OS 
I I 
0.01 0.05 
0.01 0.01 
<0.05 <0.05 
0.4 om 
I I 
1.0 0.01 
1.0 0.01 
LP 0.01 
I I 
1.0 1.0 
0.8 0.8 
0.1 0.2 
0.03 LP 
I I 
0.01 1.0 
LP 0.5 
I I 
I I 
np np 
I I 
0.6 I 
I I 
In early stage of the disease, in patients of the fifth and sixth decade, piscifonn yellow flecks at the 
level of the arcades and midperiphery were the most typical findings in this family (fig. 2a,b), 
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Most patients had additionally round drusen-like deposits (fig. 2c). These flecks became less 
apparent with age and disappeared when atrophy supervened. In the latest stage of the disease 
extensive chorioretinal atrophy and sclerosis was observed (fig. 2d). Macular (7 eyes) and 
peripapillary (3 eyes) choroidal neovascularization occurred. The onset ofneovascularization in our 
family was at the age of 49 years in one patient and after the age of 55 years in the others. Exudative 
inferior retinal detachment was observed in one patient (IV,9) (fig. 2e). Piscifoffil flecks fluoresced 
like window defects when fluorescein angiography was performed in young symptomatic patients, 
no delayed choroidal filling was observed. Fluorescein angiography in older patients showed 
chorioretinal atrophy and choroidal neovascularization. Electrophysiology and dark adaptation tests 
were only perfoffiled in a small number of patients (Table 2). In all patients the EOG was abnormal 
in an early stage of the disease and was indicative for retinal pigment epithelium dysfunction. The 
dark adaptation showed a slight elevation of rod threshold. Electroretinograms remained nOlmal 
until chorioretinal atrophy became manifest. Progressive atrophy was reflected by severe 
impainnent of rod function and relatively preserved cone function. The visual acuity in the patients 
followed the different stages of the disease. Visual acuity abruptly decreased when central 
maculopathy was observed either of disciform or atrophic nature. Extension of geographic retinal 
atrophy progressed within 4 years in patient IV, 12 with a dramatic deterioration of the visual acuity 
ITom 0.8 ODS to 0.03 OD and LP OS when the fovea became involved (fig. 3a,b) 
Table 2. Electrophysiological data oj patients with Sorsby Jundus dystrophy. 
Patient Age Visual acuity Dark adaptation EOG ERG response 
(years) (threshold log unit) (arden index) 
OD OS OD OS photopic scotopic 
1II,10 60 1 1 1.5 log U I 118% 111% slight! severe! 
1II,16 74 0 0.1 2logU! 100% 100% slight! absent 
IV,12 4660 1.0 1.0 nonnal np np normal normal 
1.0 1.0 1 log U 1 120% 111% slightl severe! 
IV,14 495659 1.0 1.0 np 118% 120% normal normal 
1.0 1.0 1logU! 120% 111% slight! severe 1 
0.8 0.8 lIog U I np np severe! absent 
IV,28 49 0 1 2logU 1 123% 128% slight! severe! 
np - not performed 
The linkage analysis with the marker D22S275 revealed a maximum lodscore of2.14 at 6 ~ 0.05 
and with marker D22S274 a maximum lodscore of 0.15 at 6 ~ 0.3 was found. Both markers 
D22S304 and D22S283 revealed significantly positive lodscores ofresp. 3.89 and 3.94 at 6 ~ 0.0. 
The results of the linkage analysis are given in Table 3. All affected individuals shared a haplotype. 
Marker D22S275 revealed a recombination in individual IV,57. Marker D22S274 revealed a 
recombination in individuals IV,IO, IV,55 and V,27. 
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Table 3. 
Locus 
D22S275 
D22S304 
D22S283 
D22S274 
Candidate genes for age-related maculopathy 
Two point Z values for linkage bet1vecn markers on chromosome 22 and SFD. 
Zat6= 
0 O.oI 0.05 0.1 0.2 0.3 0.4 
-1.95 1.68 2.14 2.11 1.69 1.08 0.42 
3.89 3.81 3.48 3.05 2.17 1.28 0.49 
3.94 3.86 3.54 3.14 2.29 1.42 0.6 
-6.78 -3.14 -1.16 -0.41 0.1 0.15 0.05 
The SSCP of the five exons, promotor region and 3'UTR showed no changes between unaffected 
and affected individuals. Nevertheless, all exons of the TIMP-3 gene were sequenced in one healthy 
person and in at least two affected individuals. No mutations possibly causing SFD were found in 
either the exons or their splice sites. A sequence gel of exon 5 of one of the affected individuals is 
shown in figure 4a. 
DISCUSSION 
In this family with Sorsby fundus dystrophy, the presence of the midpcripheral yellow pisciform 
flecks was the most typical finding. They were invariably bilateral and have not been described in 
previous Sorsby's pedigrees. The yellow flecks may correspond to the subretinal deposits that were 
reported in SFD. Such deposits were described in Bruch's membrane by Capon et a1. after a light 
and electron microscopic study of the eyes of a descendant of the Kempster family.19 A localized 
destruction of the pigment epithelium was the window defect on fluorescein angiography. In later 
stages ofthe disease progressive extensive peripheral and in some patients central atrophy occurred. 
Loss of central vision was due to disciform lesions or central geographic atrophy. 
So far, six different mutations have been identified which are implicated in SFD. These are, 
besides a splice site mutation in the intron4/exon5 junction/o Tyr168Cys,13·17 Ser181Cys,\3,21 
SerI56Cys," G1y166Cys23 and GlyI67Cys." It is remarkable that these five mutations were 
identified in a 80 bp interval at exon 5 of the TIMP-3 gene (see figure 4b). Futhennore, these five 
mutations lead to the introduction of an additional cysteine residue in the peptide sequence. In this 
SFD family we could not identify a mutation in this critical region of exon-5 (figure 4a) nor in the 
splice sites. Although linkage was found with the region 22q 12.1-q 13.2, no mutations were found in 
all five exons of the TIMP-3, including the splice sites and also the promotor region and 3'UTR 
revealed no mutations. 
Possible explanations for finding no mutations in these exons could be that the introns or 
regulatory sequences of the TIMP-3 gene contain mutations, which were not identified yet. Another 
explanation for this finding could be that the disease in this family might be caused by mutations in 
another gene located in the chromosomal vicinity of the TIMP-3 gene, similar to the heterogeneity 
on the X-chromosome where at least two RP genes are located close to each other,zs 
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GATe 
]codon 180 
124 ate aag tee tge tae tae etg eet tge ttt 
I K S C Y Y L P C F 
134 gtg aet tee aag aae gag tgt ete tgg aee 
V T S K N E C L W T 
144 gae atg ete tee aat tte ggt tae eet gge 
D M L S N F G Y P G 
154 tac'cag tee aaa eae tae gee tge ate egg 
y Q s K H Y A C I R 
C 
164 eag aag gge gge tae tge age tgg tae ega 
Q K G G Y C S W Y R 
Jcodon 140 C C C 
174 gga tgg gee eee eeg gat aaa age ate ate 
G W A P P D K S I I 
C 
184 aat gee aea gae eee tga 
N A T D P 
Figure 4 
a. Sequence of exon 5 in an affected individual with SFD. 
h. Nucleotide sequence and sequence of the conceptual translation product of exon 5. For 
previously described mutations, the rep/acing amino acid is shown underneath the 
consensus amino acid. 
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We also should consider the possibility that the disease. which is described in this paper, is 
resembling Sorsby fundus dystophy, but in fact is a different disease or a different type of SFD. An 
argument for this explanation could be that, although these spots may correspond to the subretinal 
deposits which were reported in SFD previously, in this family the presence of the rnidperipheraI 
yellow spots was the most typical finding. 
In conclusion, the family in this pedigree is suffering from an autosomal dominant fundus 
dystrophy, which is most likely Sorsby fundus dystrophy. In the linkage analysis significant 
positive lod-scores were fotmd with the region 22q12.1-q13.2. No causative mutations could be 
identified in the five exons of the TIMP-3 gene. 
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-CHAPTER 8 -
MOLECULAR EV ALUA TION OF THE ABCR GENE 
MUTATIONS IN A VARIETY OF RETINAL DISORDERS 
ABSTRACT 
The photoreceptor cell-specific ATP-binding transporter gene (ABeR), located on chromosome 
Ip21 , is exclusively expressed in the retina. Mutations in this gene have been implicated in 
Stargardt disease, and, recently, in patients with age-related macular degeneration, retinitis 
pigmentosa and cone-rod dystrophy. 
The ABCR gene is very polymorphic and is involved in several retinal diseases. Recently a 
model was postulated, which could explain a relation between the residual activity of the ABCR 
gene product and the severity of the disease phenotype. The clinical expression of the ABCR related 
disorders apparently depends on different combinations of mutations and alleles of this gene. Tn 
order to test this model, 29 unrelated individuals with a variety of retinal disorders were examined. 
The ABCR gene was screened for mutations using SSCP and direct sequencing. Tn total, ten 
mutations were found in six patients with Stargardt disease, cone rod dystrophy and cone dystrophy. 
Furthellll0re, several polymorphisms were found. Tn general our data did support and enhance the 
proposed model. However, our data indicate that the relationship between ABCR mutations and the 
resulting phenotype may be much more complex than previously thought. 
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INTRODUCTION 
The photoreceptor cell-specific ATP-binding transporter gene (ABCR), located on chromosome 
Ip21, is a member of the ATP-binding cassette transporter superfamily and expressed exclusively in 
the retina. I-5 The ABCR gene is involved in the active transport of a large variety of bie-molecules 
across the photoreceptor mernbrane.2,6 The ABCR protein is localized to the disc membrane of 
retinal rod outer segments.? 
Mutations in the ABCR gene have previously been implicated in Stargardt disease (STGD), 
a relatively common autosomal recessive monogenic retinal disorder. 6, 8"14 Stargardt disease 
(STGD) is characterized by juvenile-onset, central visual impainnent, as well as atrophic macular 
lesions sometimes surrounded by orange-yellow flecks; the so called fundus flavimaculatus. 15- 17 In 
more advanced stages of the disease, additional flecks in the midperiphery of the retina appear, 
which later on develop into atrophic fundus lesions. While the ERG potentials are nonnal in initial 
stages of the disease, they may eventually become subnonnal or abnonnal. 18 In the ABCR gene, 
about 30 different mutations were so far implicated in STGD. The majority of these represented 
missense mutations, but also three deletions and four insertions were found. 6•10 
Martinez-Mir et a1. demonstrated that a causative homozygously present mutation 
(1874de1A) in a family with retinitis pigmentosa type 19 causes a frame shift in ABCR gene." The 
heterozygous parents in this family showed no signs of retinitis pigmentosa or age-related macular 
degeneration. In a consanguineous family with individuals showing either retinitis pigmentosa or 
cone-rod dystrophy, mutations in splice sites of ABCR gene were demonstrated by Cremers et a1. 20 
An analysis of ABCR mutations in 70 British patients with recessive retinal dystrophies revealed 31 
sequence changes of which 20 were considered to be novel mutations. 21 
The ABCR gene was recently also potentially implicated in the genetically complex disorder 
age-related macular degeneration (AMD).22 AMD is the leading cause of visual impainnent in the 
western countries, affecting over 10% of people aged 75 years and over. AMD is characterized by a 
late onset and progressive central visual impainnent, and can be divided in "wet" AMD 
(neovascular) and "dry" AMD (geographic atrophy)." Although the study design, analysis and the 
conclusions were discussed, in 16% of 167 AMD patients either deletions or amino-acid 
substitutions were found in at least one allele of the ABCR gene. 24, 25 Most of these mutations were 
found in patients with the dry type of AMD. Some of the mutations were seen in AMD as well as in 
STGD patients. In contrast, two other studies did not find any support for allelic variation in ABCR 
associated with AMD. 26.27 
The ABCR gene seems to be a very polymorphic gene with involvement in a variety of 
retinal diseases. Van Driel et a1. postulated a model which provides a framework to explain the 
observed genotypes and phenotypes.' They hypothesized that most ABCR mutations could be 
classified in different classes of severity, and that, depending on the remaining total activity of 
ABCR, the phenotype can range from AMD at the mild end, to RP at the severe end of the 
spectrum. Recently, a knock-out mouse of the ABCR mouse was created.28 
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Mice lacking the ABCR gene show delayed dark adaplation. Tills is likely due to a transient 
accumulation in discs of the complex between opsin and all-trans-RAL. It wou ld be interesting to 
investigate mice with different ABCR activity (e.g. homozygous and heterozygous) in order to 
validale this model. 
In order to understand the role of ABCR in retinal disorders and to validate this model, 
mutational analys is of additional patients is warranted. In this study we examined 29 pat ients with a 
variety of retinal diseases, followed by a mutation analysis of the entire ABCR gene. 
MATERIAL AND METHODS 
PATtENTS AND DNA EXTRACTION 
All 29 umelated patients underwent a complete ophthalmo logical examination and an 
electroretinogram (ERG) was made where appropriate. All individuals were treated in accordance 
with the tenets of the Declaration of Helsinki and infoffiled consent was obtained. Patients were 
diagnosed with a large variety of retina l disorders with macular involvement, including STOD (2), 
early onset macular degeneration (2), macular dystrophy (2), autosomal dominant and recessive 
cone-dystrophy (7), cone-rod dystrophy (12), cystoid macular oedema (1), pattern dystrophy (1), 
choroidal dystrophy (I) and Bull's eye maculopathy (I). rf possible, family members of patients 
with mutations in the ABCR gene were invited to participate in this study. Blood samples of all 
individuals were obtained and standard DNA extraction protocols were followed for processing of 
these. 
PCR PRIMERS, SINGLE STRAND CONFORMATIONA L POLYMORPHISM (SSCP) ANALYSIS AND 
SEQUENCING. 
The exon/intron primers of the 50 exons of the ABCR gene used for SSCP analysis are described 
elsewhere.8 PCR was essentially performed as described elsewhere. 29 Three different PCR reaction 
conditions were llsed for the different primers. SSCP analyses were perfolmed as described 
elsewhere.30 If any band shifts were detected in the gel, further analysis with direct sequencing was 
performed, and additional mutation analysis was perfonned in at least 130 contro l chromosomes to 
exclude potential polymorphism. 
RESULTS 
Mutational analysis of the ABCR gene in 29 patients with a variety of retinal disorder with macular 
involvement was carried out. The ophthalmological findings of patients with mutations in the 
ABCR gene are presented in Table 1. Altogether, 10 apparently functional mutations, not present in 
at least 130 control chromosomes, were identified in tw"o patients with STGD, three patients with 
cone-rod dystrophy and in one patient with cone dystrophy. 
87 
Table 1. The results of the ophthalmic examinations. 
Family Diagnosis Age of onset Visual Acuity Ophthalmoscopy ERG 
I 
number OD OS 
25902 Stargardt disease 7 years 0.05 0.05 macular alterations scotopic decreased ! 
photopic residual activity 
25797 Stargardt disease 7 years 0.01 0.01 macular alterations, flavimaculatus not performed I 
pigment clumping in the periphery 
25532 Cone-rod dystrophy 7 years 0.Q2 0.02 sclerotic macular alterations, RPE spiculae scotopic as well as 
photopic absent 
25479 Cone-rod dystrophy 3 years 0.1 0.25 dystrophy of the macula, pale optic nerve, scotopic as well as 
narrow vessels photopic decreased 
25815 Cone-rod 32 years 0.05 0.05 macular alterations, bull's eye maculopathy scotopic: 85% ofnonnal 
dystrophy values 
photopic: 12% ofnonnal 
values 
20681 Cone dystrophy 8 years 0.25 0.25 pigmentary in changes in the macula cone dystrophy 
._-
Table 2. Mutation analysis of patients with several eye diseases with macular involvement 
P-number diagnosis exon mutation nucleotide change control diagnosis with same mutation, described in earlier 
aminoacid chromosomes reports 
25902 Stargardt disease 17 G863A G2588C 2/172 STGD(Allikmetsot31, Cromers etal) Al\ID(Allibnetsetal) 
43 G1977S G5929A 01184 STGD(Rozet et,l) 
46 Splice site 6385+2 C~>G (a) 
25797 Stargardt disease 22 EI087K G3259A 0/162 . 
48 6543del36 bp 51170 (b) 
25532 Cone-rod dystrophy 33 11562T T4685C 01130 Al\m(AlIikmru .. aLl 
35 R1640W C4918T 01186 STGD(Raz.t et.l) 
25479 Cone-rod dystrophy 44 L2027F C6079T 2/194 STGD(N)sonkin et.1. AlHkmets e! all 
25815 Cone-rod dystrophy 17 Splice site 2588-12 C->G (e) 
20681 Cone dystrophy 6 R212H G635A 61140 
-
ecc) Splice score of consensus sequence: 0.4; ;;Vith 8385+2 C->G it remains 0.4 
(dd) In the same region Allilcmets et a1. found a deletion of one nucleotide (6568~C) in a patient with AMD. And in the same exon (48) they found an 11 bp deletion at position 
6519 in one AMD patient. 
(ee) Splice score of consensus sequence: 8.0; with 2588-12 C->G splice score: 6.1 
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The majority ofthe mutations were single nucleotide alterations at conserved amino acids positions. 
The summarized results ofthe mutation analysis are presented in Table 2. 
MUTATION ANALYSIS OF ABCRIN STARGARDTDlSEASE. 
Ophthalmoscopy of the affected members in pedigree (P)25902 (Figure 1) showed macular 
alterations compatible with Stargardt disease. The electroretinogram of the proband showed a 
residual photopic activity as well as a reduced scotopic activity. Besides the maculopathy, diffuse 
flecks were seen in the posterior pole of the fundus. Mutation analysis of the entire ABCR gene in 
patient 1II,4 of P25902 revealed two heterozygously present mutations (G863A and G1977S) and a 
mutation in the splice site of exon 46. 
Wild type ~'D Wild type 
Exon 46 splice site 
O~ Exon 17 G863A Exon 43 Gl77S Exon 46 splice site 
Exon 17 G863A 
Exon43 GI77S 
Wild type 
Figure 7 The pedigree offamily 25902 with STGD with the segregation analysis of 
respectively mutations G863A, G1977S and 6385+ 3 C->G. Males are represented 
by squares and females are represented by circles; blackened symbols represent 
affected individuals. The black bar indicates the mutations found in the proband 
of this family (III,4) 
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The G863A mutation was previously described by AHikmets (1997) in patients with STGD and 
AMD (Table 2) as well as in a small number of healthy individuals. We found this sequence change 
also in two out of 172 control chromosomes. Amplification of exon 43 revealed a nucleotide 
substitution, with a predicted replacement of serine for glycine at amino residue 1977 (G1977S) 
which was not present in 184 control chromosomes. In the same patient an additional 
(heterozygously present) mutation was found in the splice site of exon 46 (6385 + 2 C->G). The 
splice site potential score, according to Shapiro and Senapathy did not change; it remains 77.1. 31 
Segregation analysis in the family 25902 showed that mutation G863A and G 1977S were inherited 
from the mother, while the potential splice site mutation was derived from paternal side (Figure 1). 
In patient 25797 with STGD, ophthalmological examination showed macular alterations 
compatible with STGD, as well as flavimaculatus flecks in the posterior pole. An ERG was 
performed in 1982, which showed a decrease in photopic and scotopic activity. Mutational analysis 
of the entire ABCR gene revealed one mutation (E 1 078K) and a 36 bp deletion. Exon 22 revealed a 
sequence substitution, which would replace a glutamate at amino-residue 1078 with lysine 
(E1078K), and would possibly introduce a change in polarity in the predicted protein. This mutation 
was not seen in the 162 control chromosomes. Furthermore, a deletion of 36 bp (6543L136bp) was 
found in the analysis of exon 48, which does not alter the reading frame, but apparently will cause a 
predicted protein of reduced size. This deletion, however, was also found in five out of 170 control 
chromosomes and might therefore be a polymorphism. The observed nucleotide change and the 
deletion were found only in one allele of the ABCR gene, while the other allele revealed the wild-
type sequence. DNA of additional family members was not available for further studies to formally 
prove potential compound heterozygosity in this patient. 
MUTATlON ANALYSIS OF ABCR IN CONE-ROD DYSTROPHY. 
The proband of family 25532 showed sclerotic macular alterations at ophthalmoscopy. The findings 
of the ERG were consistent with cone-rod dystrophy. Mutational analysis of the ABCR gene in this 
patient revealed mutation I1562T in exon 33 which was described before by AHikmets (1997), but, 
in contrast with our finding, only in patients with AMD (Table 2). Upon further analysis of ABCR 
in this patient exon 35 revealed a heterozygously present nucleotide substitution which would 
replace in the predicted protein a positively charged arginine with the neutral tryptophan at amino-
residue 1640 (RI640W). This could affect the folding of the predicted protein. Both mutations were 
not seen in at least 130 control chromsomes. Mutation analysis of the ABCR gene in the family 
members is shown in Figure 2. The Il562T mutation in exon 33 is maternal where the mutation in 
exon 35 should be paternal (DNA of the father was not available). The proband in this family is 
therefore compound heterozygous. 
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Exon 33 Il562T ~'. 
Exon 35 R1640W U 0 
Exon 33 I1562T 
Wild type 
Exon 33 11562T 
Wild type 
Wild type 
Wild type 
Figure 8 The pedigree offamily 25532 with cone-rod dystrophy with the segregation 
analysis of respectively mutations JJ 562T and Rl640W. Males are represented by 
squares and females are represented by circles; blackened symbols represent 
affected individuals. 
Fundus examination of the proband of family 25479 showed dystrophy of the macula with a pale 
optic nerve and narrow vessels. The ERG findings confirmed a cone-rod dystrophy. DNA analysis 
of the ABCR gene revealed a nucleotide substitution in eXOD 44, which would replace a leucine at 
amino residue 2027 with phenylalanine (L2027T) in the predicted protein. This mutation was also 
described before, but only in patients with STGD by both Allikmets and Nasonkin (Table 2). In two 
out of 194 control chromosomes this sequence change was also present. No family members were 
available for segregation analysis. 
Ophthalmological examination of proband P25815 revealed a decreased visual acuity with 
macular alterations in both fundi. ERG showed a decrease in scotopic activity (70% of nonnal 
values) as well as in photopic activity (20% of normal values). Mutation analysis of the ABCR 
revealed a splice site mutation at exon 17 (2588-12 C->G). 
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The splice potential score of the consensus sequence was 79.9, whereas the splice potential score 
with this mutation was 77.4 according to Shapiro and Senapathy. No family members were 
available for segregation analysis. 
MUTA nON ANALYSIS OF ABCR IN CONE-DYSTROPHY. 
In P20861 an autosomal dominant cone-dystrophy is segregating in the family. Fundus 
examinations of the proband showed pigmentalY changes in the macula, pale optic nerve and 
nonnal blood vessels. No pigmentary changes were seen in the periphery. The ERG showed nonnal 
scotopic responses but reduced photopic responses, conform the diagnosis cone dystrophy. 
Mutational analysis of the ABCR gene in the proband revealed the heterozygously presence of a 
nucleotide substitution in exon 6. This would replace an arginine with a histidine at amino residue 
212 (R212H). This mutation was found in six out of 140 control chromosomes. Interestingly, none 
of the other affected family members revealed this mutation, nor any other mutation. 
Table 3. Apparently nonfunctional changes. 
nucleotide change amino acid change exon 
C6069T 120231 44 
C6249T 120831 45 
T6285C D2095D 46 
G2829A R943Q 19 
sequence changes intron cryptic splice site 
4668~58 c-> T IVS33 no 
4773+48 C->T IVS33 no 
4774-15 GT ins IVS34 no 
6282+7 G->A IVS45 no 
POLYMORPHISMS 
Besides the functional sequence alterations described above, a number of apparently non-functional 
changes were observed (See Table 3). In two patients with cone-rod dystrophy, the analysis of exon 
46 revealed a T6285C nucleotide substitution, which would not yield a different amino acid 
(D2095D). Moreover, this sequence change was also found in eight out of 80 control 
chromosomes. This suggests the presence of a neutral polymorphism. 
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Furthermore, two missense mutations (C6069T; C6249T) were found in at least one control 
individual, suggesting that they are infrequent neutral polymorphisms, and four, apparently non-
functional, sequence changes were found in introns. These sequence changes did not introduce a 
cryptic splice site according to splice site calculations and were apparently not present in any 
potential regulatory sequences. The analysis of exon 19 revealed a G2829A nucleotide substitution 
(R943Q) in three patients (with STDO, cone-rod dystophy and Bull's eye maculopathy), but this 
nucleotide change was found in 10% of the control chromosomes. Allilanets et al reported the latter 
variaut in 24 out of16? AMD patients and in 24 out of 220 control persons. 
DISCUSSION 
In 29 unrelated patients with a variety of retinal disorders, we identified mutations in five probands. 
In total ten different mutations were found. The majority of these mutations were single nucleotide 
alterations at conserved amino acids positions, but also a 36 bp deletion was found. Both STGD 
patients included in this study did carry mutations in the ABCR gene. In three patients with cone-
rod dystrophy mutations were found in the ABCR gene as well as in one patient with cone 
dystrophy. In the other patients no mutations could be identified in the ABCR-gcne. 
MUTATION ANALYSIS OF ABCR IN STARGARDT DISEASE 
The mutational segregation patterns in family P25902 are of interest, since the complex allele 
_segregating in this pedigree carries, besides a previous described nucleotide change (G863A) a 
novel mutation (G5929A) on a single allele and on the other allele a mutation in a splice site. This 
result indicates, first of all that in mutation studies of the ABCR gene, all of the exons of the gene 
should be checked carefully for the presence of multiple (additional) sequence alterations on a 
single allele. Secondly, given the unaltered splice site potential score of 77.1, one expects the splice 
mutation to be only a mild mutation. 
We applied our data to the model proposed by van Driel et al. If one considers the G 1977S 
or the G863A to be a severe mutation on one allele with the mild splice site mutation on the other 
aBele, then these mutations would fit in this model and the phenotype-genotype correlation model 
would be justified. Moreover, if only one allele is affected, one would assume that the STGD in this 
family would be an autosomal dominant disease, while, in contrast, the parents were consanguinous 
and unaffected. Another option is that the combination of mutations 0863A and 01977S in one 
allele would cause a strong reduced ABCR activity, with a mildly affected other allele caused by the 
splice site mutation. According to van Driel et a1. mutation G863A is a mild mutation, which seems 
to be quite often involved in STOD patients in the Netherlands.12 However, 0863A is not only 
found in patients with AMD aud STOD but also in controls. Therefore, it is more likely that the 
G177S would cause a more severe effect. Moreover, the G1977S mutation is located in the second 
ATP binding site. So, most likely the 01977S mutation is a severe mutation, which strongly 
reduces the ABCR activity. 
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In the ABCR gene of the other Stargardt disease patient (P25797), a 36 bp deletion was found in 
one allele. Although this deletion was also found in some of the control chromosomes, it is 
interesting that it occured in the same protein domain as a deletion reported by Allikmets et al. 
(1997) in a patient with AMD (6568t.C). Moreover, in the sarne exon AlIikmets et a1. described an 
11 bp deletion at position 6519 in a patient with AMD as well as in a STGD patient. According to 
their location, these deletions might influence the second nucleotide binding fold. The exact 
pathogeneity ofthis deletion prone region remains to be established. 
MUTATION ANALYSIS OF ABCR IN CONE-ROD DYSTROPHY. 
In patient 25532 with cone-rod dystrophy, we found the I1562T mutation in combination with 
R1640W. Interestingly, the first mutation was described by Allikmets et a1. in patients with AMD 
while the latter is found in STGD patients. Apparently the combination of mutations causes cone-
rod dystrophy. According to the proposed model of van Driel et aI, these mutations could fit in the 
model: the mutations are located in different alleles. 
In patient 25815 with cone-rod dystrophy, only a heterozygously present potential mutation 
in the splice site could be identified, with a small reduction of the splice site potential score. This 
would not fit in the proposed model, in which is suggested that two alleles should he affected. 
The L2027F mutation, which was the only mutation we found in patient 25974 with cone-
rod dystrophy, was also found heterozygously in patients with STGD (Nasonkin et al). This would 
not fit in the model and it remains unclear why the same mutation without any other sequence 
alteration in ABCR would cause different phenotypes. 
MUTATION ANALYSIS OF ABCRIN CONE-DYSTROPHY. 
In one patient with cone-dystrophy (20681) a sequence change (R212H) was found in exon 6. This 
change was also found in control chromosomes and not found in any of the other affected family 
members. This implies that this change might be only a polymorphism and that it is not involved in 
the development of cone dystrophy. 
CONCLUSIONS 
Combining our data with those of the literature, the (clinical) expression of the ABCR related 
disorders apparently depends on different combinations of mutations or sequence substitutions of 
this gene. Our data show that a number of sequence changes can occur on a single allele. 
Consequently, all exons of ABCR should be checked carefully for the presence of multiple 
(additional) sequence alterations on a single or both allele(s). Specific combinations of mutations 
may lead to specific phenotypes; however, futher mutational analysis of ABCR and genotype-
phenotype studies are needed to elucidate the reason why a mutation, apparently, without any other 
sequence alteration in ABCR would cause different phenotypes. 
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-CHAPTER 9 -
VARIANTS IN THE ABCR GENE ASSOCIATED 
WITH AGE-RELATED MACULAR DEGENERATION 
ABSTRACT 
Age-related macular degeneration (AMD) accounts for over 50% of the registered visual disability 
among the elderly Caucasians in the Western World, and has been associated both with 
environmental factors such as smoking and genetic factors. Previously we have reported disease-
associated variants in the ABCR gene in a subset of patients affected with this complex disorder. 
We have now tested our original hypothesis, that ABCR is a dominant susceptibility locus for 
AMD, by screening 1385 unrelated AMD patients of Caucasian origin and 1478 comparison 
individuals from 15 centers in N. America and Europe for the two most frequent variants found in 
ABCR. These two sequence changes, G 1961 E and D2177N, were found in one allele of ABCR in 
53 patients (-4%), and in 13 controls (-0.9%). Fisher's two-sided exact test confiImed that these 
two variants are associated with AMD at a statistically significant level (P < 0.0001), and the results 
remain significant on an independent sample, after exclusion of the data from the previous study (P 
< 0.0001). The risk of AMD is elevated about 3,fold in D2177N carriers and about 7,fold in 
G1961E carriers; the two variants together account for about 3% of AMD. Mutations were found 
more commonly in subjects diagnosed as having the dry (non-neovascular) fann than in those with 
the exudative [OIm of the disorder (P ~ 0.003). The identification of a gene that confers risk of 
AMD is an important step in unraveling this complex disorder. 
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Age-related macular degeneration (AMD) is a complex human disorder estimated to affect at least 
11 million individuals worldwide, and is the most common cause of acquired visual impainnent in 
people over the age 60 years. !-3 Prevalence increases with age; among persons 75 years and older, 
mild fonns occur in nearly 30% and advanced forms in about 7%,2 Visual loss in AMD is due to 
either choroidal neovascularization or geographic atrophy, which occur as a reaction to age-changes 
at the level of the retinal pigment epithelium and Bruch's membrane.4-S The clinical heterogeneity, 
late onset, and complex etiology of the disorder render genetic studies in AMD extremely difficult. 
Recently, we identified the rod photoreceptor-specific, ATP-binding cassette transporter gene, 
ABCR, as the causative gene for recessive juvenile macular dystrophy, Stargardt disease (STGDl): 
We subsequently reported several heterozygous amino acid-changing, disease-associated, 
alterations in ABCR in patients diagnosed with AMD.7 However, several have challenged the 
statistical analyses,8 and one investigation did not find an association between ABCR alterations 
andAMD' 
In the absence of a functional assay for ABCR activity, a good strategy to evaluate the role 
of ABCR in AMD is to assess the association of DNA sequence variants of ABCR with the AMD 
phenotype in case-control studies. Application of the family-based transmission disequilibrium test 
(TDT)lO to control for population stratification is difficult because typically one cannot genotype 
parents of patients with this late onset disease, although sibling-based studies would be possible. 
Previous case-control association studies of rare ABCR variants in AMD patients have been 
problematic because of relatively small sample sizes, differences in ascertainment of both cases and 
controls, and differences in methods of data analysis in each individual study.7.9 To overcome these 
limitations, we assembled an International Consortium to screen for variants of the ABCR gene in 
large, regionally diverse populations of both subjects and control populations. The International 
Consortium for ABCR screening includes 15 ophthalmic centers and laboratories from eight 
countries (Table I). Each center was tasked: (i) to diagnose independently and to collect a new and 
independent set of patients with AMD; (ii) to examine and to collect a control population; and (iii) 
to screen all collected DNA samples for the presence of three selected variants - G1961E, D2177N 
and R943Q by the screening method of its choice. ll To assure proper genotyping, each center was 
provided with positive controls for each of the three variants. A comparison group was matched for 
ethnicity, and, as indicated in Table 1, some centers selected a population above 64 years of age 
("age-matched" controls, AM) whereas other centers selected from the general population (GP). 
The two variants G1961E and D2177N, which lead to non-conservative missense amino acid 
substitutions, were detected in about 4% of patients each in our previous study and were deemed 
associated with the AMD phenotype7 The R943Q polymorphism was used to assess comparability 
of case and control populations, to compare populations between centers, and to decide if pooling of 
data was appropriate. In our earlier report, the R943Q variant had been found in excess in the 
control population,7, 8 a discrepancy explained by incomplete screening of all cohorts. 12 
The results are summarized in Table 1. The D2177N variant was detected in 28 (2.1 %) out 
of the total 1356 AMD patients, and in 9/1478 (0.61 %) of the age-matched and general population 
controls (two-sided Fisher's exact P ~ 0.0007). 
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Center 
Science study (7) 
Boston Utah 
Baltimore 
Houston 
los Angeles 
Wuerzburg 
Nijmegen 
Rotterdam 
Amsterdam 
Naples 
Milan 
Barcelona 
UppsaJa 
london 
Paris 
Total 
P" 
80th variants 
Without Science 
study 
,-
Both variants 
GP, general population 
AM, age-matched 
D, dry fonn of AMD 
W, wet form of AMD 
Population 
Caucasian 
American 
Caucasian 
American 
Caucasian 
American 
Caucasian 
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3 (2/1) 0 
0 0 
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1 (0/1) 0 
0 0 
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53/1356 13/1478 
(3.91%) (0.88%J. 
19/1218 411258 
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40/1189 12/1258 
(3.36%) (0.95%) 
D2177N R943Q 
AMD Cant. AMD (fJ/WJ lGP/AML Cont. 
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3 (2/1) 2 (0/2) 18/200 41100 (9%L (4%) 
1 (1/0) 3 (3/0) 8183 33/308 (9.6%) (10.7%) 
0 1 (0/1) 5163 11/93 (11.8%) (7.9%) 
0 0 
5168 
8/171 (4.7%) (7.4%) 
1 (0/1) 0 4136 (11.1% 4/34 (11.8%) 
2 (1/1) 0 12/98 7190 (12.2%) (7.8%) 
1 (0/1) 0 4190 0/20 (4.4%) (0%) 
2 (0/2) 1 (1/0) 4172 6/107 (5.6%) (5.6%) 
28/1356 911478 100/1263 129/1514 
(2.1%) (0.61%) . (7.9%) (8.5%) 
p= 0,00072 p= 0,5866 
P < 0,0001 
21/1189 811258 
(1.77%) (0.64%) 
p= 0.014 
P < 0.0001 
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Unless otherwise stated, all p values are based on the two-sided Fisher's exact testY The 
corresponding odds ratio, calculated from exact conditional methods13 was 3.3 with 95% confidence 
interval (1.5, 8.0). Thus, carriers of the D2177N mutation have 3.3 times the risk of developing 
AMD as non-carriers. Similar results were obtained when the analysis was stratified on type of 
control (age matched versus general population) or on study center, and there was no statistically 
significant evidence of heterogeneity of odds ratios across centers. The proportion of AMD 
attributable to this mutation, the attributable risk, 14 is estimated as only 1.5% (0.6%, 2.3%), because 
the allele is rare in the general population. 
Twenty-five (1.8%) of 1385 AMD cases canied the Gl961E variant, compared to 411478 
(0.27%) of controls, (P < 0.0001). The relative odds ratio was 6.8 (2.3, 27), and the attributable risk 
was 1.5% (0.8%, 2.3%). Despite that fact that caniers of GI961E have 6.8 times the risk of non-
carriers, this allele explains no more AMD than does D2177N, because GI961E is rarer (0.27%). 
Similar odds ratios were obtained if the analysis was stratified on type of control or on study center, 
and there was no statistically significant evidence of heterogeneity across centers. Together, the two 
variants were detected in 5311356 (3.91%) of individuals with AMD and in 1311478 (0.88%) of 
controls, (P < 0.0001), and the proportion of disease attributable to having either variant is 3.1% 
(1.9%,4.2%), No case or control possessed both variants. 
In Table I we present the data from the current study as well as previously published 
results. 7 In order to test our earlier hypothesis that ABCR variants are statistically significantly 
associated with AMD, we excluded our earlier results7 from these analyses. Without those data, the 
association of the two variants with AMD is still significant: P ~ 0.001 for the GI961E variant and 
P ~ 0.01 for the D2177N amino acid change. Together, these two variants are found in 4011189 
patients and in 1211258 controls (P < 0.0001). Therefore the data from this expanded study 
independently support our earlier conclusions about the association of pathogenic variants in 
patients with AMD. 
Although it is possible that the association of AMD with variants of ABCR is due to other 
umelated gene(s) that cause AMD and that are in disequilibrium with these variants of ABCR, there 
are several reasons why this is unlikely. Whereas a single uncommon mutation, such as GI96IE, 
might be in linkage disequilibrium with a putative disease-causing gene, it is unlikely that two rare 
variants within the same ABCR gene would be in linkage disequilibrium with that gene. This is 
especially so because there is no evidence that GI961E and D2177N tend to occur together. More 
probable explanations are that these two variants are both causally related to AMD through their 
action on the ABCR protein, or in linkage disequilibrium with other, currently unknown, ABCR 
mutations. Preliminary data from photoaffinity labeling experiments indicate that at least one of 
these variants, G1961E, is indeed a pathogenic mutation. The mutant Gl961E protein, produced 
following the transfection of293 cells with cloned cDNA, exhibits several fold lower binding of 8-
azido-ATP than the wild-type ABCR protein (Y. Sun and 1. Nathans, personal commnnication). 
The D2177N variant had no effect on 8-azido-ATP binding, suggesting that this change may go 
nndetected in this in vitro assay system or that D2177N is in linkage disequilibrium with a 
pathogenic ABCR mutation. It is of interest to note that, unlike G1961E, the D2177N variant so far 
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has not been detected in patients with Stargardt disease." 15·17 Data for the R943Q polymorphism 
also provides evidence against the possibility that another gene causes the association of AMD with 
GI961E and D2177N. There is no association between R943Q and AMD in these data (p= 0.58 
with odds ratio 0.92 (.70, 1.00), nor is there evidence of heterogeneity of odds ratios across centers 
(Breslow-Day test p=.75).13 If a nearby mutation in another gene were the cause of AMD, one 
might expect it to be in disequilibrium with one or more polymorphisms of ABCR such as R943Q. 
Another possibility is that the association of AMD with GI961E and with D2177N stems fi'om 
improper choice of controls ("population stratification"). as can occur when cases originate from 
one sUbpopulation and controls from another subpopulation of an admixed population. In Table 1, 
however, higher levels of GI961E and D2177N are found in AMD cases than controls in practically 
each study center. It is unlikely that population stratification would occur consistently in such 
diverse populations. These data thus provide the strongest evidence to date that some variants in 
ABCR are associated with phenotypes of age-related macular degeneration. 
In this study, we analyzed the two most prevalent disease-associated variants described in 
our earlier study,7 The reported genetic heterogeneity of ABCR alleles in various eye diseases, 
including STGD 1, is remarkable. 6, 9, J5, l6 The vast majority of disease-associated alleles are rare and 
often reported only in single cases.7, 9, 15 At the same time the reported mutation detection efficiency 
in ABCR even in STGDI patients has ranged from 60-70% of alleles in some studies, 15. 16 to 20-
30% in the others.9, 17 Together, these data indicate that both the numbers of affected individuals 
analyzed and the efficiency of mutation detection techniques must be increased significantly to 
correctly assess the fraction of ABCR variants involved in AMD cases. We have reported 
previously that ABCR variants are more prevalent among subjects manifesting the dry (non-
neovascular) fonn of the disease. 7 Distinction between the dry and wet phenotypes is not 
unambiguous. 9 This relates to lack of unifonnity in clinical classification, in which the tenn AMD 
may be used to denote any age-change whatever the vision or to those with visual loss as a 
consequence. In the first case the term dry refers to those with drusen only as well as those with 
visual loss so that patients classified as dry represent 90% of cases.4 In the second, the term dry 
refers to those with geographic atrophy only that represent a minority of cases. Whether or not these 
two clinical manifestations have different genetic risk factors remains to be elucidated, 
Occasionally, individuals with the dry fonn in one eye may develop choroidal neovascularization 
later in life either in the same or fellow eye,18 Each participating clinician in this Consortium 
segregated its patient popUlation by phenotype, between those with the dry form, characteIized by 
drusen, RPE pigmentary abnormalities, and/or geographic atrophy; and those manifesting the wet, 
or exudative (neovascular), stage. 19, 20 For the purposes of these analyses, when different 
phenotypes appeared in the two eyes, the assignment of the disease status was based on the more 
severely affected eye, 
Of the 1385 patients analyzed, 667 had the dry phenotype and 718 had the exudative form 
(Table I). The proportion of patients diagnosed with the exudative complication was much higher 
in European centers compared to those from North AmeIica (Table l). If analyzed separately, 
association of the two sequence changes with AMD was more prominent in N. American subset 
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(data not shown). Altogether, the G1961E variant was detected in 17/667 (2.55%) patients with the 
dry forrn, compared to 81718 (1.1%) of those with the wet forrn (p ~ 0.044). The corresponding 
odds ratio, 2.4 (1.0, 6.4), indicates that Gl96lE was found 2.4 times more commonly in those 
designated as having dry lesions as with wet AMD. Similarly, the D2l77N mutation was found in 
19/648 (2.93%) of patients with the dry and in 91708 (1.27%) of patients with the wet phenotype 
(p~ 0.036), and the corresponding odds ratio was 2.3 (1.0, 5.9). Together, these two variants were 
present in 36/648 patients with non-exudative disease and in 171708 with exudative lesions (p ~ 
0.0030). This observation may explain the difference between N. American and European centers 
and the lack of association between ABCR variants and AMD found in another study,9 where morc 
tban 60% of the 182 emolled patients were reported to manifest the exudative phenotype. The 
difference in the ratio of wet and dry betvveen centers may reflect different criteria used to select 
cases or genuine variance in the prevalence of difference phenotypes in diverse populations 
subjected to a variety of environmental pressures. Although we have demonstrated that variants in 
ABCR are associated predominantly with non-exudative AMD, the clinical relevance of this finding 
remains to be detennined. Future studies, with larger numbers of affected individuals and controls, 
may be able to link allelic variants in ABCR to specific disease phenotypes. 
Knowledge of the relationship of individual ABCR alterations to the AMD phenotype(s) 
will pennit a better understanding of this complex disorder, and will facilitate detection of other 
genetic and environmental risk factors. The influence of each ABCR variant on the protein function 
and on pathogenesis of AMD has yet to be evaluated. Functional studies of this ABC transporter 
have implicated all-trans retinal or its conjugates with phosphatidylethanolamine (PE), N-
retinylidene-PE and N-retinylidene-N-retinylethanolamine (A2E), as potential substrates 21.22 for the 
protein. Mice homozygous for a null mutation in ABCR accumulate higher levels of a major 
fluorophore of lipofuscin, A2E, in the retinal pigment epithelium (RPE). 22 Additional supportive 
evidence for the potential role of ABCR variants in AMD is being sought from studies on 
segregation of ABCR variants in Stargardt pedigrees in which elderly members manifest AMD. 
Several reports have indicated an increased rate of AMD in parents and grandparents of STGD 
patients, harboring ABCR variants. 15· 23-27 
In summary, we have tested our hypothesis that some ABCR variants are associated with 
AMD, on a large and diverse collection of subjects and controls. Overall this association is 
statistically significant for at least these two known mutations. The G1961E and D2177N variants 
alone are detected in about 4% of these geographically diverse subjects with AMD. These variants 
in the ABCR gene are associated predominantly with the dry, non-neovascular, disease phenotype. 
The risk of AMD is increased about three-fold in carriers of D2l77N and about seven-fold in 
carriers of G1961E, and these two variants account for about 3% of AMD cases, which in the 
context of common complex disorders represents an important contribution to the disease load. 
Since AMD affects millions of people worldwide and the described mutations represent only two 
out of thirteen reported earlier,7 the number of people at increased risk of developing age-related 
maculopathy, as carriers for variant ABCR alleles, is substantial. As more genes are identified the 
true contribution of ABCR to the disorder will become clearer. Our experience indicates that very 
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large numbers of cases will be required to accomplish the objectives, and it is likely that success can 
only be achieved by fonnation of large International Consortia using carefully planned and unified 
protocols. 
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-CHAPTER 10-
GENERAL DISCUSSION 
In this general discussion a brief overview will be given of the major findings, together with 
methodological considerations. Special attention is addressed to some issues of consideration when 
studying the genetics of a genetically complex disease such as age-related maculopathy (ARM). 
Finally, I will provide recommendations for future research. 
DISEASE FREQUENCY AND RISK FACTORS 
Prevalences of ARM have been studied in several epidemiological studies. 1-5 In Chapter 3, we have 
combined the data of three studies from three different continents; Australia, North America and 
Europe. The prevalence of AMD was consistently found to increase with age. Besides age, smoking 
was the only risk factor found in all three studies. Remarkably, the prevalence of AMD in the 
Rotterdam Study was lower than in the other two studies. In Rotterdam, where we studied the 
incidence of AMD at 2-year follow-up, we also found a lower incidence of AMD at all ages 
compared to the Beaver Dam Eye study.6 
Selection bias can be a reason for the lower prevalences and incidences in Rotterdam. The 
overall response rate was reasonably good at base-line (78%), as well as after 2 years of follow-up 
(79%). It is, however, lower than in the other studies. The non-participants were older and more 
likely to be diseased. This would mean that the Rotterdam population was healthier, which would 
decrease the ascertained prevalence and incidence of the disease. In reality these percentages may 
be higher than our studies indicate. 
Infonnation bias could occur due to misclassification. In these studies we have made a great 
effort to classify ARM as correctly as possible. We have used the international classification and 
grading system and all available ophthalmological infonnation to diagnose ARM.7 We have tested 
interobserver and intraobserver variation, using weighted kappa values. Furthennore, all diagnoses 
of AMD were confinned by the principal investigators on all three continents. 
GENETIC EPIDEMIOLOGY OF AGE-RELATED MACULOPATHY 
Many investigators have described that genetic factors are involved in ARM8 ,,, Genetic studies of 
ARM have, however, been hampered by the lack of suitable patient material due to the late age of 
onset, the clinical heterogeneity of the disorder and phenocopies. In chapter 5 a simple method is 
described which facilitates identification of families with a high genetic risk. 
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This is done by using age-specific prevalences of ARM in the general population and observed 
frequencies of ARM in a family. In this study we used a case-control design; families of cases with 
AM]) were compared with families of controls without any signs of ARM. In contrast to familial 
aggregation studies, the family unit was respected. For small families sizes, the family score method 
is more unreliable as it is uncertain whether the family score is the result of genetic risk or just 
coincidence. This method is more useful for studies in molecular genetics than it is for clinicians, 
since no effective treatment for ARM is known. 
In chapter 6 a large family derived from an isolated community is described. Genetic 
isolates are advantageous for the study of genetically complex diseases: the number of founders is 
limited which reduces the number of mutations residing in the population considerably. In this 
family we perfonned a genomic screening for ARM by using about 400 marker loci. In the initial 
analysis we investigated three candidate loci or genes, chromosome lq, ABCR gene and TIMP-3 
gene. 15•17 Although these three loci are apparently not cosegregating with ARM in this family, they 
can not be excluded on the basis of our results as a candidate gene for ARM, since it is, of course, 
possible that due to the relatively small sample size these results are falsely negative. It will be of 
great interest to see which locus or loci are associated with ARM in this pedigree. Cunently, further 
research is being perfonned to test the five regions with a high chi-square for a disease locus. 
Additional markers will be tested in these regions. Since in this analysis multiple markers with 
multiple alleles are used, a higher statistical significance level will be required. The height of this 
significance level is debatable. 18 Since a genetic isolate is not a good reflection of the general 
popUlation, it is possible that genes which are associated with ARM in this pedigree are not 
associated with ARM in the general population. These genes could, however, give clues to the 
pathogenesis of ARM. 
CANDIDATE GENES FOR AGE-RELATED MACULAR DEGENERATION 
Many candidate genes were suggested to be involved in ARM. Candidate genes may be selected 
from their known function, their chromosomal position or their known involvement in other fonns 
of inherited retinal degeneration. Two known candidate genes for ARM are TIMP-3, which is 
involved in Sorsby fundus dystrophy (SFD), and ABCR, which is known to be involved in 
Stargardt disease. 16• 17 
In chapter 7 of this thesis we examined a large family with SFD. SFD is thought to be a 
monogenic disease due to mutations in the TIMP-3 gene on chromosome 22. In this family, SFD 
was linked to the region of chromosome 22 in which TIMP-3 is located. However, no mutations 
could be identified in TIMP-3. There may be mutations in regions of the gene, like intronic 
sequences, which are not investigated in the current study. Another possible explanation is that a 
different gene is located in the vicinity ofTIMP-3, which is involved in this pedigree. 
The ABCR gene is a photoreceptor cell-specific ATP-binding transporter gene, located on 
chromosome 1 p21 and is exclusively expressed in the retina. 19,2o ABCR is phosphorylated in 
response to light, which suggests that it plays a role in phototransduction. 
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Mutations in this gene have been implicated in Stargardt disease and cone-rod dystrophy as well as 
in retinitis pigmentosa type 19,16,21-27 We have investigated the ABCR gene in a variety of retinal 
disorders in order to investigate the mutations in ABCR in relation to the phenotype. Since ABCR 
exhibits a large genetic variability associated with a number of retinal disorders, it is important to 
describe the pheno- genotype relation accurately. Why and how the same mutation without any 
other sequence alteration in ABCR would cause different phenotypes has yet to be solved. 
In chapter 9 a large collaborative effort involving several study groups was initiated. The 
first publication of Allikmets et a!., in which he claimed an association of ABCR variants in 
unrelated AMD cases in comparison to a control group, resulted in a major scientific debate. 28 
Major points of discussion were flaws in study design and analysis as well as potential 
misc1assification of the cases. Moreover, the overall frequency of variations did not significantly 
differ between the case and control group (p=OJ).29. JO Two other studies could not confinn these 
data. J !· J2 In our collaborative study, a total of 1385 cases with ARM and 1478 controls were 
examined for two mutations in ABCR. These mutations, G1951E and D2177N, were the ones most 
often associated with ARM in the previous study. In the current study, single strand confonnational 
polymorphism (SSCP) techniques to identity mutations in ABCR and additional sequence analyses 
were performed. Positive controls with the two mutations were used to prevent false negative 
results; a negative control was also used to prevent false positive results. To prevent systematic 
errors, the reading of the gels was done masked to the disease status. A different frequent variation, 
R943Q, was used to test whether the different populations could be compared to each other. 
Population admixture might lead to a false positive association. No significant difference in the 
frequency of R943Q could be observed between the different populations. The other two mutations 
were found to occur at a statistically significant higher rate in ARM cases than in the controls. 
Although the ABCR gene is unlikely to alter over time, it may be useful to analyse mutations in the 
ABCR gene in incidental cases. 
STRATEGIES FOR FUTURE RESEARCH 
In most epidemiologic studies a cross~sectional design is used, and infonnation on disease 
prevalence is provided. For research on the etiology of diseases, data based on incidence is preferred 
over prevalence. Incidence represents the actual occurrence of the disease. The exposure to potential 
risk factors is measured before the onset of disease, and identified risk factors are therefore more 
likely to be causal. Incidence data on ARM would improve OUT knowledge of the etiology and the 
progression of the disease. More incidence studies with a large fol1ow-up are still needed to provide 
more accurate estimates of the incidence of ARM and to identify its risk factors. 
One of the major problems in the genetic study of a late onset disease such as ARM is the 
lack of suitable patient material. Parents are often deceased, while the younger generation does not 
yet have the disease on a clinical level. Most families are limited to sibships. Linkage analyses in 
families are therefore often impossible. Large families with multiple affected individuals are scarce. 
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A different method based on family relations of the cases is the affected sibpair method, in which 
affected sibpairs are examined and the haplotypes of both sibs are compared. This technique is 
based on the principle of inherited alleles which are identical by decent. If at a certain locus more 
alleles are inherited identical by descent than expected, this would indicate a candidate locus for the 
disease. For genomic screening, many affected sibpairs would be needed for such a complex disease 
as ARM. Association studies are also not well-suited for a genomic screening in large, mixed 
populations. One would need tens of thousands of markers to screen the whole genome, because 
linkage disequilibrium extends over very short distances. Moreover, testing many markers would 
elevate the required significance level tremendously. Genomic search may be more feasible in a 
genetically isolated population in which fewer genes and mutations are involved in the disease, due 
to common founders among the cases. 
In contrast to linkage analysis and allele sharing methods, association studies do not concern 
familial inheritance patterns at all. Unrelated cases are compared with a control group. This 
facilitates data collection remarkably. If candidate genes are identified, association studies are used 
to demonstrate a correlation between functionally relevant allelic variation and the risk of disease in 
humans. 
In the human genome project, whole chromosomal regions will be sequenced in order to 
identify genes in these regions. Some of these genes will be candidates and may eventually prove to 
be disease-causing genes for ARM. 
For complex diseases, like ARM, the most powerful strategy may prove to be the allele 
sharing method in a genetically isolated population. The idea is to find many affected individuals 
who have inherited the same disease-causing gene from a common ancestor. The affected 
inidividuals will tend to have a shared haplotype in the region of the disease-causing gene. Since 
data on many historical meisoses are incorporated in this method, the number of recombinations 
will be higher, therefore mapping the disease causing-gene to a smaller region. 
FINAL REMARKS 
The aim of this thesis was to provide more insight into the frequency of ARM and its risk factors, in 
particular the genetic factors. I feel that this thesis has advanced our knowledge about the 
pathogenesis of ARM. Concerning the genetic factors, many studies and collaborations are needed 
to investigate all candidate loci and genes. With the identification of the molecular defects 
underlying ARM, intervention in the processes leading to ARM may come within reach. 
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SUMMARY 
This thesis describes a genetic and epidemiologic approach to age-related maculopathy. Age-related 
maculopathy (ARM) is a disorder of the yellow spot in the eye (the macula), and it affects people 
over 55 years of age. ARM consists of a variety of clinical signs, from the early stages with soft 
distinct drusen, indistinct drusen and pigment alterations up to the late stages, characterized by 
geographic atrophy and neovascular macular degeneration. These late stages are also referred to as 
age-related macular degeneration (AMD). Several risk factors are reported to be associated with 
ARM. Aging and smoking are the two most important and were consistently found. Besides these 
and others, genetic factors playa role in ARM. 
In Chapter 2 an overview is given of the genetic factors involved in ARM, which are 
described in the literature. One of the main problems in the genetic studies on ARM is the lack of 
suitable patient materia1. Parents are often deceased while in the younger generations the disease 
has not yet manifested itself on a clinical level. Families available for genetic studies are therefore 
mostly limited to sibships with ARM. Moreover, ARM is a genetically complex disorder in which 
several genes and mutations are involved. Cases with ARM might also arise from non-genetic risk 
factors; these are called phenocopies. In this chapter methods are discussed which can be used in the 
research of genetic complex diseases such as ARM. 
In chapter 3 and 4 the disease frequency of ARM is described. The prevalence (chapter 3) 
and the incidence (chapter 4) were investigated in the Rotterdam Study. In this study 7983 
individuals were examined for ophthalmological, neurological, cardiovascular and locomotor 
diseases. Gradable fundus photographs were available for 6411 individuals. The diagnosis AMD 
was made in 104 cases (1,6%). In Chapter 3 this is compared with two other studies, the Beaver 
Dam Eye study and the Blue Mountain study. The age-specific prevalence of neovascular macular 
degeneration was lower in the Netherlands compared to the other two studies. Age-specific 
incidences of AMD also appeared to be lower in Rotterdam than in Beaver Dam. In 2 years, 2 per 
100 subjects of our total study population developed AMD. The course of the disease was 
examined. Subjects with indistinct drusen with pigmentary alterations in the macular area were 
most at risk. 
Chapter 5 shows a method to identify families with a high genetic risk of AMD. Families of 
AMD-affected individuals can be divided into three groups of genetic risk; low, intermediate and 
high. 
In Chapter 6 a large family with ARM oliginating from a genetic isolate is identified. A 
whole genome screening with 400 markers was carried out. Three c-andidate loci/genes, the ABCR 
gene, chromosome 1 q25-31 and TIMP3 gene, were tested and excluded form involvement in ARM 
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in this pedigree. In the genomic screening five interesting regions with a high chi-square were 
identified. These regions will be investigated in more detail in the near future. 
Chapter 7 describes a pedigree with Sorsby fundus dystrophy in which the TIMP3 gene is 
investigated. In the literature mutations in eXOll 5 of this gene are associated with this disorder. In 
our study, Sorsby fundus dystrophy was linked to the region on chromosome 22 in which TIMP3 is 
located, however we could not identify any mutation in TIMP3 gene. Especially, no mutations in 
exon 5 were found. 
The potential role of the ABCR gene is described in Chapters 8 and 9. The ABCR gene is 
exclusively expressed in the retina and is associated with Stargardt disease, retinitis pigmentosa and 
cone-rod dystrophy. ABCR is also potentially implicated in AMD. In Chapter 8 several retinal 
disorders were investigated for mutations in ABCR. In five of the 29 patients examined we found 
mutations in the ABCR gene. In Chapter 9 the results of a large collaborative effort are given. 
Fifteen study groups worldwide examined two mutations, D2177N and G1951E, in AMD patients 
compared to controls. These two mutations were significantly more frequent in the case group. 
Chapter 10 provides a general discussion on all the studies described in this thesis, and 
makes recommendations for future research. 
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SAMENVATTING 
In dit proefschrift wordt cen genetisch epidemiologische studie naar ouderdoms maculopathie 
beschreven. Dit is cen aandoening van de gele vlek in het DOg die met name op oudere leeftijd 
voorkomt. De gele vlek in het Dog moet intact zijn om scherp te kmmen zien, gezichten tc 
herkennen en te lezen. Bij de eindstadia van ouderdoms maculopathie, dat zijn geografische atrotic 
en neovasculaire maculadegeneratie, is dit functioneren verstoord en ontstaat een visuele handicap. 
Deze eindstadia noemt men ouderdomsmaculadegencratie (OMD). Van OMD is reeds een aantal 
risicofactoren beschreven; toenemende lecftijd en roken zijn tot dusver de beiangrijkste en worden 
in elk onderzoek oak geassocieerd met OMD. Naast deze en andere risicofactoren spelen ook 
genetische oorzaken een roi. 
In hoofdstuk 2 wordt een overzicht gegeven van de genetische factoren, die een rol spelen 
bij OMD. Een van de grote problemen van het genetische onderzoek naar OMD is het gebrek aan 
patientenmateriaal. Door de late leeftijd waarop OMD ontstaat zijn de ouders van een persoon met 
OMD vaak overleden, terwijl de kinderen de ziekte nog niet hebben. Hierdoor is het familie-
onderzoek vaak beperkt tot broers en zussen met OMD. Verder zijn er waarschijnlijk diverse genen 
en mutaties betrakken bij het ontstaan van OMD. Bovendien kan OMD bij een persoon natuurlijk 
ook het gevolg zijn van een niet genetische oorzaak (bijvoorbeeld roken). In het hoofdstuk worden 
tevens methoden besproken die toepasbaar zijn voor het onderzoek naar genetisch complexe ziekten 
zoals OMD. 
In de hoofdstukken 3 en 4 wordt het voorkomen van de ziekte beschreven. De prevalentie 
(hoofdstuk 3) en de incidentie (hoofdstuk 4) zijn bepaald in het ERGO bevolkingsonderzoek. 
ERGO staat voor Erasmus Rotterdam Gezondheid en Ouderen. Hierin zijn 7983 personen 
onderzocht op oogziekten, aandoeningen van het bewegingsapparaat, neurologische en 
cardiovasculaire aandoeningen. Van 6411 personen zijn er scherpe, goed gradeerbare foto's 
beschikbaar. Bij 104 personen (1,6%) is de diagnose eindstadia OMD gestcld. In hoofdstuk 3 wordt 
dit vergeleken met twee andere studies, de Beaver Dam studie en de Blue Mountain studie. Daaruit 
bleek dat in Nederland de oogaandoening pas op latere Jeeftijd in dezelfde frequentie voorkomt. Dit 
wordt ook waargenomen in hoofdstuk 4 waarin de incidentie wordt vergeleken met de Beaver Dam 
studie. In tweejaar onwikkelden twee op de 1000 personen in onze studie een eindstadium. Tevens 
is het natuurlijk verloop van de aandoening bestudeerd en daaruit bleek dat met name personen met 
onscherp begrensde witte vlekjes op de retina (drusen) met veranderingen in het retinaal 
pigmentepitheel de grootste kans hebben op het krijgen van een eindstadia. 
In hoofdstuk 5 wordt een methode beschreven waarrnee families met een hoog genetisch 
risico voor OMD gei'dentificeerd kunnen worden. Families met personen met OMD kunnen worden 
opgedeeld naar laag, middelmatig verhoogd en sterk verhoogd genetisch risico. Eike stijging van 
familie-score geeft een risico (p) van 1.3 gecorrigeerd voor leeftijd, geslacht en raken. 
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In hoofdstuk 6 wordt een methode toegepast die goed bruikbaar is voer genetisch complexe 
aandoeningen, namelijk tlgenome screening" in een genetisch isolaat. In een genetisch isolaat 
kunnen veel personen door middel van stamboomonderzoek aan elkaar verbonden worden. In het 
onderzoek kon van 21 aangedane personen met zowel voor- als eindstadia van OMD een grate 
familie worden herleid. In deze familie zijn bijna 400 markers getest, die verspreid over het gehele 
genoom liggen. Drie kandidaat regio's c.q. genen, te weten het ABCR-gen, chromosoom Iq25-31, 
en het TIMP3-gen konden worden uitgesloten van betrokkenheid bij OMD in deze stamboom. 
Momenteel zijn er over het hele genoom vijf interesante gebieden gevonden die mogelijk betrokken 
kunnen zijn bij OMD in deze familie. Verder onderzoek naar deze gebieden zal nog worden 
uitgevoerd. 
In hoofdstuk 7 wordt het TIMP3-gen, dat verantwoordelijk is voor Sorsby fundus dystrofie, 
nader bekeken in een stamboom waarin deze aandoening voorkomt. Tot nu toe zijn in de literatuur 
aIleen mutaties in exon 5 van dit gen geassocieerd met deze aandoening. In deze studie is 
aangetoond dat Sorsby fundus dystrofie in deze familie gekoppeld is aau het gebied op chromosoom 
22 waar het TIMP3-gen zich bevindt. Er zijn echter geen mutaties gevonden die verantwoordelijk 
kunnen zijn voar deze dystrofie in deze stamboom, met name zijn er geen mutaties in exon 5 van 
het TIMP3-gen gevonden. 
In hoofdstuk 8 en 9 wordt gekeken naar het ABCR-gen. Het ABCR-gen komt specifiek in 
de retina voer en is geassocieerd met Stargardt fundus dystrofie, retinitis pigmentosa en cone-rod 
dystrophy. Er zijn aanwijzingen dat ABCR-mutaties geassocieerd zijn met OMD. In hoofdstuk 8 
worden verschillende retinale aandoeningen beschreven met de ABCR mutaties die daarbij 
gevonden zijn. Bij vijf van de 29 onderzochte patienten zijn mutaties in het ABCR-gen gevonden. 
In hoofdstuk 9 wordt een samenwerking tussen 15 verschillende centra over de wereld beschreven, 
waarbij naar twee specifieke mutaties is gekeken in een grote groep personen met OMD en een 
grote controIe-groep. Het is gebleken dat deze mutaties, D2177N en G1951E, relatief vaak 
voorkornen bij de groep met OMD in vergelijking tot de controle-groep. 
In hoofdstuk 10 worden aIle bevindingen van de voorgaande hoofdstukken bediscussieerd 
en worden aanbevelingen gedaan voor verder onderzoek. 
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